BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389:1741-1755. [PMID: 27914655 DOI: 10.1016/s0140-6736(16)31711-1] [Cited by in Crossref: 615] [Cited by in F6Publishing: 285] [Article Influence: 102.5] [Reference Citation Analysis]
Number Citing Articles
1 Oh K, Oh EH, Noh SM, Park SH, Kim N, Hwang SW, Park SH, Yang D, Byeon J, Myung S, Yang S, Ye BD. Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy. Clin Transl Gastroenterol 2022;Publish Ahead of Print. [DOI: 10.14309/ctg.0000000000000442] [Reference Citation Analysis]
2 Kaiko GE, Chen F, Lai CW, Chiang IL, Perrigoue J, Stojmirović A, Li K, Muegge BD, Jain U, VanDussen KL, Goggins BJ, Keely S, Weaver J, Foster PS, Lawrence DA, Liu TC, Stappenbeck TS. PAI-1 augments mucosal damage in colitis. Sci Transl Med 2019;11:eaat0852. [PMID: 30842312 DOI: 10.1126/scitranslmed.aat0852] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
3 Revés J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov 2021;2:100070. [PMID: 34988431 DOI: 10.1016/j.crphar.2021.100070] [Reference Citation Analysis]
4 Con D, van Langenberg DR, Vasudevan A. Deep learning vs conventional learning algorithms for clinical prediction in Crohn's disease: A proof-of-concept study. World J Gastroenterol 2021; 27(38): 6476-6488 [PMID: 34720536 DOI: 10.3748/wjg.v27.i38.6476] [Reference Citation Analysis]
5 Li L, Ma J, Hua X, Zhou Y, Qiu Y, Zhu Z, Zheng Y, Xie Q, Liang Z, Xu J. Altered Intra- and Inter-Network Functional Connectivity in Patients With Crohn’s Disease: An Independent Component Analysis-Based Resting-State Functional Magnetic Resonance Imaging Study. Front Neurosci 2022;16:855470. [DOI: 10.3389/fnins.2022.855470] [Reference Citation Analysis]
6 Zhao F, Zheng T, Gong W, Wu J, Xie H, Li W, Zhang R, Liu P, Liu J, Wu X, Zhao Y, Ren J. Extracellular vesicles package dsDNA to aggravate Crohn's disease by activating the STING pathway. Cell Death Dis 2021;12:815. [PMID: 34453041 DOI: 10.1038/s41419-021-04101-z] [Reference Citation Analysis]
7 Chen J, Zhou J, Yang J, Cong R, Sun J, Xiao J, Shi J, He B. Efficiency of dual-energy computed tomography enterography in the diagnosis of Crohn's disease. BMC Med Imaging 2021;21:185. [PMID: 34861843 DOI: 10.1186/s12880-021-00716-y] [Reference Citation Analysis]
8 Sharma S, Gupta A, Kedia S, Agarwal S, Singh N, Goyal S, Jain S, Gupta V, Sahu P, Vuyyuru SK, Kante B, Sharma R, Panwar R, Sahni P, Makharia G, Ahuja V. Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn's disease. Intest Res 2021;19:291-300. [PMID: 32447877 DOI: 10.5217/ir.2019.09172] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Park MY, Yoon YS, Lee JL, Park SH, Ye BD, Yang SK, Yu CS. Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn's disease: a retrospective observational study. Stem Cell Res Ther 2021;12:401. [PMID: 34256838 DOI: 10.1186/s13287-021-02484-6] [Reference Citation Analysis]
10 Liu J, Gong W, Liu P, Li Y, Zheng T, Hong Z, Ren H, Gu G, Wang G, Wu X, Zhao Y, Ren J. Trocar Puncture With a Sump Drain for Crohn's Disease With Intra-Abdominal Abscess: A 10-Year Retrospective Cohort Study. Front Surg 2022;9:816245. [DOI: 10.3389/fsurg.2022.816245] [Reference Citation Analysis]
11 Huang M, Tian W, Luo S, Xu X, Yao Z, Zhao R, Huang Q. Duration of postoperative hyperlactatemia has predictive value in recurrent fistula after major definitive surgery for intestinal fistula. BMC Surg 2022;22:14. [PMID: 35033052 DOI: 10.1186/s12893-022-01465-7] [Reference Citation Analysis]
12 Schwarzfischer M, Rogler G. The Intestinal Barrier—Shielding the Body from Nano- and Microparticles in Our Diet. Metabolites 2022;12:223. [DOI: 10.3390/metabo12030223] [Reference Citation Analysis]
13 Faleck DM, Shmidt E, Huang R, Katta LG, Narula N, Pinotti R, Suarez-Farinas M, Colombel JF. Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis. Clin Gastroenterol Hepatol 2021;19:238-245.e4. [PMID: 32569749 DOI: 10.1016/j.cgh.2020.06.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
14 Shi L, Han X, Li JX, Liao YT, Kou FS, Wang ZB, Shi R, Zhao XJ, Sun ZM, Hao Y. Identification of differentially expressed genes in ulcerative colitis and verification in a colitis mouse model by bioinformatics analyses. World J Gastroenterol 2020; 26(39): 5983-5996 [PMID: 33132649 DOI: 10.3748/wjg.v26.i39.5983] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
15 Rustgi SD, Kayal M, Shah SC. Sex-based differences in inflammatory bowel diseases: a review. Therap Adv Gastroenterol. 2020;13:1756284820915043. [PMID: 32523620 DOI: 10.1177/1756284820915043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Alharbi O, Almadi MA, Azzam N, Aljebreen AM, AlAmeel T, Schreiber S, Mosli MH. Clinical characteristics, natural history, and outcomes of Crohn's-related intra-abdominal collections. Saudi J Gastroenterol 2021;27:79-84. [PMID: 33723092 DOI: 10.4103/sjg.SJG_89_20] [Reference Citation Analysis]
17 da Cunha VP, Preisser TM, Santana MP, Machado DCC, Pereira VB, Miyoshi A. Mycobacterial Hsp65 antigen delivered by invasive Lactococcus lactis reduces intestinal inflammation and fibrosis in TNBS-induced chronic colitis model. Sci Rep 2020;10:20123. [PMID: 33208841 DOI: 10.1038/s41598-020-77276-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Buisson A, Vazeille E, Fumery M, Pariente B, Nancey S, Seksik P, Peyrin-Biroulet L, Allez M, Ballet N, Filippi J, Yzet C, Nachury M, Boschetti G, Billard E, Dubois A, Rodriguez S, Chevarin C, Goutte M, Bommelaer G, Pereira B, Hebuterne X, Barnich N; CEALIVE & REMIND study group. Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive E. coli in Crohn's disease. United European Gastroenterol J 2021;9:1007-18. [PMID: 34791806 DOI: 10.1002/ueg2.12161] [Reference Citation Analysis]
19 Zhao D, Yang B, Ye C, Zhang S, Lv X, Chen Q. Enteral nutrition ameliorates the symptoms of Crohn's disease in mice via activating special pro-resolving mediators through innate lymphoid cells. Innate Immun 2021;27:533-42. [PMID: 34791916 DOI: 10.1177/17534259211057038] [Reference Citation Analysis]
20 Yu ZQ, Wang WF, Zhu CZ, Zhang KH, Chen XC, Chen JY. The Polymorphism rs17525495 of LTA4H Is Associated with Susceptibility of Crohn's Disease instead of Intestinal Tuberculosis in a Chinese Han Population. Biomed Res Int 2019;2019:9537050. [PMID: 31093505 DOI: 10.1155/2019/9537050] [Reference Citation Analysis]
21 Ito N, Takeuchi I, Kyodo R, Hirano Y, Sato T, Usami M, Shimizu H, Shimizu T, Arai K. Features and Outcomes of Children with Ulcerative Colitis who Undergo a Diagnostic Change: A Single-Center Experience. Pediatr Gastroenterol Hepatol Nutr 2021;24:357-65. [PMID: 34316470 DOI: 10.5223/pghn.2021.24.4.357] [Reference Citation Analysis]
22 Ye C, Zhu S, Yuan J. Construction of ceRNA Network to Reveal Potential Biomarkers in Crohn's Disease and Validation in a TNBS Induced Mice Model. J Inflamm Res 2021;14:6447-59. [PMID: 34880646 DOI: 10.2147/JIR.S338053] [Reference Citation Analysis]
23 Zhang MN, Shi YD, Jiang HY. The risk of dementia in patients with inflammatory bowel disease: a systematic review and meta-analysis. Int J Colorectal Dis 2022. [PMID: 35325272 DOI: 10.1007/s00384-022-04131-9] [Reference Citation Analysis]
24 Wu Y, Chen Y, Chen H, Yang C, Shen X, Deng C, Sun N, Wu H. Probing serum N-glycan patterns for rapid and precise detection of Crohn's disease. Chem Commun (Camb) 2021;57:11362-5. [PMID: 34643622 DOI: 10.1039/d1cc04699c] [Reference Citation Analysis]
25 Regev S, Odes S, Slonim-Nevo V, Goren G, Friger M, Greenberg D, Vardi H, Schwartz D, Sergienko R, Sarid O. Normative data for the Brief Symptom Inventory for patients with Crohn's disease. Psychol Health 2021;:1-12. [PMID: 33410712 DOI: 10.1080/08870446.2020.1862841] [Reference Citation Analysis]
26 Rui M, Fei Z, Wang Y, Shi F, Meng R, Shang Y, Ma A, Li H. Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-Analysis. Front Med (Lausanne) 2021;8:679258. [PMID: 34540859 DOI: 10.3389/fmed.2021.679258] [Reference Citation Analysis]
27 Takenaka K, Tominaga K, Kanazawa M, Fukushi K, Tanaka T, Kanamori A, Sugaya T, Tsuchida K, Iijima M, Goda K, Irisawa A. Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. Sci Rep 2019;9:17751. [PMID: 31780764 DOI: 10.1038/s41598-019-54369-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Łukawska A, Ślósarz D, Zimoch A, Serafin K, Poniewierka E, Kempiński R. Cumulative Effective Dose from Medical Imaging in Inflammatory Bowel Disease. Diagnostics (Basel) 2021;11:2387. [PMID: 34943623 DOI: 10.3390/diagnostics11122387] [Reference Citation Analysis]
29 Wang L, Dong X, Feng S, Pan H, Jang X, Chen L, Zhao Y, Chen W, Huang Z. VX765 alleviates dextran sulfate sodium-induced colitis in mice by suppressing caspase-1-mediated pyroptosis. Int Immunopharmacol 2022;102:108405. [PMID: 34865993 DOI: 10.1016/j.intimp.2021.108405] [Reference Citation Analysis]
30 Matsuda H, Nibe-shirakihara Y, Tamura A, Aonuma E, Arakawa S, Otsubo K, Nemoto Y, Nagaishi T, Tsuchiya K, Shimizu S, Ma A, Watanabe M, Uo M, Okamoto R, Oshima S. Nickel particles are present in Crohn's disease tissue and exacerbate intestinal inflammation in IBD susceptible mice. Biochemical and Biophysical Research Communications 2022;592:74-80. [DOI: 10.1016/j.bbrc.2021.12.111] [Reference Citation Analysis]
31 Lee C, An M, Joung JG, Park WY, Chang DK, Kim YH, Hong SN. TNFα Induces LGR5+ Stem Cell Dysfunction In Patients With Crohn's Disease. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00224-1. [PMID: 34700029 DOI: 10.1016/j.jcmgh.2021.10.010] [Reference Citation Analysis]
32 Nakamura S, Imaeda H, Nishikawa H, Iimuro M, Matsuura M, Oka H, Oku J, Miyazaki T, Honda H, Watanabe K, Nakase H, Andoh A. Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study. Intest Res 2018;16:554-62. [PMID: 30301337 DOI: 10.5217/ir.2018.00027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
33 Yu H, Shen YQ, Tan FQ, Zhou ZL, Li Z, Hu DY, Morelli JN. Quantitative diffusion-weighted magnetic resonance enterography in ileal Crohn's disease: A systematic analysis of intra and interobserver reproducibility. World J Gastroenterol 2019; 25(27): 3619-3633 [PMID: 31367161 DOI: 10.3748/wjg.v25.i27.3619] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Skamnelos A, Lazaridis N, Vlachou E, Koukias N, Apostolopoulos P, Murino A, Christodoulou D, Despott EJ. The role of small-bowel endoscopy in inflammatory bowel disease: an updated review on the state-of-the-art in 2021. Ann Gastroenterol 2021;34:599-611. [PMID: 34475730 DOI: 10.20524/aog.2021.0652] [Reference Citation Analysis]
35 Li J, Hou W, Lin S, Wang L, Pan C, Wu F, Liu J. Polydopamine Nanoparticle-Mediated Dopaminergic Immunoregulation in Colitis. Adv Sci (Weinh) 2021;:e2104006. [PMID: 34713621 DOI: 10.1002/advs.202104006] [Reference Citation Analysis]
36 Silverman J, Salwen B, Goren I, White I. Concomitant intestinal malrotation and Crohn's disease: a rare and surgically challenging anomaly. J Surg Case Rep 2022;2022:rjac152. [PMID: 35422992 DOI: 10.1093/jscr/rjac152] [Reference Citation Analysis]
37 Ayyar KK, Moss AC. Exosomes in Intestinal Inflammation. Front Pharmacol 2021;12:658505. [PMID: 34177577 DOI: 10.3389/fphar.2021.658505] [Reference Citation Analysis]
38 Huo JH, Wang XY, Gong L, Gu X. Role of regulatory B cells in autoimmune diseases of the digestive system. Shijie Huaren Xiaohua Zazhi 2020; 28(12): 486-492 [DOI: 10.11569/wcjd.v28.i12.486] [Reference Citation Analysis]
39 Huang S, Li L, Ben-Horin S, Mao R, Lin S, Qiu Y, Feng R, He Y, Chen B, Zeng Z, Chen M, Zhang S. Mucosal Healing Is Associated With the Reduced Disabling Disease in Crohn's Disease. Clin Transl Gastroenterol 2019;10:e00015. [PMID: 30839440 DOI: 10.14309/ctg.0000000000000015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
40 Caër C, Wick MJ. Human Intestinal Mononuclear Phagocytes in Health and Inflammatory Bowel Disease. Front Immunol 2020;11:410. [PMID: 32256490 DOI: 10.3389/fimmu.2020.00410] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
41 Molendijk I, van der Marel S, Maljaars PWJ. Towards a Food Pharmacy: Immunologic Modulation through Diet. Nutrients 2019;11:E1239. [PMID: 31159179 DOI: 10.3390/nu11061239] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
42 Li Z, Kuang X, Chen T, Shen T, Wu J. Peptide YY 3-36 attenuates trinitrobenzene sulfonic acid-induced colitis in mice by modulating Th1/Th2 differentiation. Bioengineered 2022;13:10144-58. [PMID: 35443853 DOI: 10.1080/21655979.2022.2064147] [Reference Citation Analysis]
43 Azimirad M, Tajbakhsh M, Yadegar A, Zali MR. Recurrent urinary tract infection with antibiotic-resistant Klebsiella pneumoniae in a patient with Crohn's disease: A case report. Clin Case Rep 2021;9:e04531. [PMID: 34401151 DOI: 10.1002/ccr3.4531] [Reference Citation Analysis]
44 Rencz F, Stalmeier PFM, Péntek M, Brodszky V, Ruzsa G, Gönczi L, Palatka K, Herszényi L, Schäfer E, Banai J, Rutka M, Gulácsi L, Lakatos PL. Patient and general population values for luminal and perianal fistulising Crohn's disease health states. Eur J Health Econ 2019;20:91-100. [PMID: 31102158 DOI: 10.1007/s10198-019-01065-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Lo B, Burisch J. Artificial intelligence assisted assessment of endoscopic disease activity in inflammatory bowel disease. Artif Intell Gastrointest Endosc 2021; 2(4): 95-102 [DOI: 10.37126/aige.v2.i4.95] [Reference Citation Analysis]
46 Li CM, Chen Z. Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation. Front Cell Dev Biol 2021;9:664305. [PMID: 34235145 DOI: 10.3389/fcell.2021.664305] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Crooks B, Barnes T, Limdi JK. Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. Drugs Context. 2020;9:2019-10. [PMID: 32180822 DOI: 10.7573/dic.2019-10-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Gu Z, Duan M, Sun Y, Leng T, Xu T, Gu Y, Gu Z, Lin Z, Yang L, Ji M. Effects of Vitamin D3 on Intestinal Flora in a Mouse Model of Inflammatory Bowel Disease Treated with Rifaximin. Med Sci Monit 2020;26:e925068. [PMID: 33177483 DOI: 10.12659/MSM.925068] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Germain A, Chateau T, Beyer-Berjot L, Zerbib P, Lakkis Z, Amiot A, Buisson A, Laharie D, Lefèvre JH, Nancey S, Stefanescu C, Bresler L, Peyrin-Biroulet L; GETAID Chirurgie. Surgery for Crohn's disease during pregnancy: A nationwide survey. United European Gastroenterol J 2020;8:736-40. [PMID: 32326876 DOI: 10.1177/2050640620921060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Yu ZQ, Wang WF, Dai YC, Chen XC, Chen JY. Interleukin-22 receptor 1 is expressed in multinucleated giant cells: A study on intestinal tuberculosis and Crohn's disease. World J Gastroenterol 2019; 25(20): 2473-2488 [PMID: 31171891 DOI: 10.3748/wjg.v25.i20.2473] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Műzes G, Bohusné Barta B, Sipos F. Colitis and Colorectal Carcinogenesis: The Focus on Isolated Lymphoid Follicles. Biomedicines 2022;10:226. [PMID: 35203436 DOI: 10.3390/biomedicines10020226] [Reference Citation Analysis]
52 Cao Y, Su Q, Zhang B, Shen F, Li S. Efficacy of stem cells therapy for Crohn's fistula: a meta-analysis and systematic review. Stem Cell Res Ther 2021;12:32. [PMID: 33413661 DOI: 10.1186/s13287-020-02095-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
53 Miyazaki C, Katsumasa N, Huang KC, Liu YF. Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan. PLoS One 2021;16:e0254807. [PMID: 34280242 DOI: 10.1371/journal.pone.0254807] [Reference Citation Analysis]
54 Bertani L, Barberio B, Fornili M, Antonioli L, Zanzi F, Casadei C, Benvenuti L, Facchin S, D'antongiovanni V, Lorenzon G, Ceccarelli L, Baglietto L, de Bortoli N, Bellini M, Costa F, Savarino EV, Fornai M. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.03.008] [Reference Citation Analysis]
55 Lawton J, Achit H, Pouillon L, Boschetti E, Demore B, Matton T, Tournier C, Prodel M, Peyrin-Biroulet L, Guillemin F. Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience. United European Gastroenterol J 2019;7:908-13. [PMID: 31428415 DOI: 10.1177/2050640619853448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
56 Burke JP. Role of Fecal Diversion in Complex Crohn's Disease.Clin Colon Rectal Surg. 2019;32:273-279. [PMID: 31275074 DOI: 10.1055/s-0039-1683916] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
57 Li J, Zuo L, Tian Y, He Y, Zhang Z, Guo P, Ge Y, Hu J. Spontaneous colitis in IL-10-deficient mice was ameliorated via inhibiting glutaminase1. J Cell Mol Med 2019;23:5632-41. [PMID: 31211512 DOI: 10.1111/jcmm.14471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
58 Araruna ME, Serafim C, Alves Júnior E, Hiruma-Lima C, Diniz M, Batista L. Intestinal Anti-Inflammatory Activity of Terpenes in Experimental Models (2010-2020): A Review. Molecules 2020;25:E5430. [PMID: 33233487 DOI: 10.3390/molecules25225430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Wang X, Wan J, Wang M, Zhang Y, Wu K, Yang F. Multiple sclerosis and inflammatory bowel disease: A systematic review and meta‐analysis. Ann Clin Transl Neurol. [DOI: 10.1002/acn3.51495] [Reference Citation Analysis]
60 Xiang L, Ding X, Li Q, Wu X, Dai M, Long C, He Z, Cui B, Zhang F. Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment? MicrobBiotechnol. 2020;13:760-769. [PMID: 31958884 DOI: 10.1111/1751-7915.13536] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
61 Vollenberg R, Tepasse P, Lorentzen E, Nowacki TM. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study. JPM 2022;12:694. [DOI: 10.3390/jpm12050694] [Reference Citation Analysis]
62 Babenko VV, Millard A, Kulikov EE, Spasskaya NN, Letarova MA, Konanov DN, Belalov IS, Letarov AV. The ecogenomics of dsDNA bacteriophages in feces of stabled and feral horses. Comput Struct Biotechnol J 2020;18:3457-67. [PMID: 33294140 DOI: 10.1016/j.csbj.2020.10.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Kameli N, Becker HEF, Welbers T, Jonkers DMAE, Penders J, Savelkoul P, Stassen FR. Metagenomic Profiling of Fecal-Derived Bacterial Membrane Vesicles in Crohn's Disease Patients. Cells 2021;10:2795. [PMID: 34685776 DOI: 10.3390/cells10102795] [Reference Citation Analysis]
64 Lin R, Chen H, Shu W, Sun M, Fang L, Shi Y, Pang Z, Wu W, Liu Z. Clinical significance of soluble immunoglobulins A and G and their coated bacteria in feces of patients with inflammatory bowel disease. J Transl Med 2018;16:359. [PMID: 30558634 DOI: 10.1186/s12967-018-1723-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
65 Joher N, Gosset C, Guerrot D, Pillebout E, Hummel A, Boffa JJ, Faguer S, Rabant M, Higgins S, Moktefi A, Delmas Y, Karras A, Lapidus N, Amiot A, Audard V, El Karoui K. IgA nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review. Nephrol Dial Transplant 2021:gfaa378. [PMID: 33416845 DOI: 10.1093/ndt/gfaa378] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Hunt JE, Holst JJ, Jeppesen PB, Kissow H. GLP-1 and Intestinal Diseases. Biomedicines 2021;9:383. [PMID: 33916501 DOI: 10.3390/biomedicines9040383] [Reference Citation Analysis]
67 Macdonald GG, Koehn C, Attara G, Stordy A, Allerdings M, Leese J, Li LC, Backman CL. Patient Perspectives on the Challenges and Responsibilities of Living With Chronic Inflammatory Diseases: Qualitative Study. J Particip Med 2018;10:e10815. [PMID: 33052129 DOI: 10.2196/10815] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
68 Mir A, Nguyen VQ, Soliman Y, Sorrentino D. Wireless Capsule Endoscopy for Diagnosis and Management of Post-Operative Recurrence of Crohn's Disease. Life (Basel) 2021;11:602. [PMID: 34201514 DOI: 10.3390/life11070602] [Reference Citation Analysis]
69 Papamichael K, Jairath V, Zou G, Cohen B, Ritter T, Sands B, Siegel C, Valentine J, Smith M, Vande Casteele N, Dubinsky M, Cheifetz A. Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open 2022;12:e057656. [PMID: 35365535 DOI: 10.1136/bmjopen-2021-057656] [Reference Citation Analysis]
70 Lubrano E, Luchetti MM, Benfaremo D, Mauro D, Ciccia F, Perrotta FM. Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician. Expert Rev Clin Immunol 2021;17:1199-209. [PMID: 34622735 DOI: 10.1080/1744666X.2021.1991315] [Reference Citation Analysis]
71 Troncoso LL, Biancardi AL, de Moraes Jr HV, Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. World J Gastroenterol 2017; 23(32): 5836-5848 [PMID: 28932076 DOI: 10.3748/wjg.v23.i32.5836] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 25] [Article Influence: 9.6] [Reference Citation Analysis]
72 Thomsen SB, Ungaro RC, Allin KH, Elmahdi R, Poulsen G, Andersson M, Colombel JF, Jess T. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study. Aliment Pharmacol Ther 2022. [PMID: 35080036 DOI: 10.1111/apt.16777] [Reference Citation Analysis]
73 Ungaro F, Garlatti V, Massimino L, Spinelli A, Carvello M, Sacchi M, Spanò S, Colasante G, Valassina N, Vetrano S, Malesci A, Peyrin-Biroulet L, Danese S, D'Alessio S. mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease. Cells 2019;8:E924. [PMID: 31426584 DOI: 10.3390/cells8080924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
74 Zhu C, Yu Y, Wang S, Wang X, Gao Y, Li C, Li J, Ge Y, Wu X. A Novel Clinical Radiomics Nomogram to Identify Crohn's Disease from Intestinal Tuberculosis. J Inflamm Res 2021;14:6511-21. [PMID: 34887674 DOI: 10.2147/JIR.S344563] [Reference Citation Analysis]
75 Cavalcanti E, Armentano R, Lolli I. Crohn's Disease Following Rituximab Treatment for Follicular Lymphoma in a Patient with Synchronous Gastric Signet Ring Cells Carcinoma: A Case Report and Literature Review. Cancer Res Treat 2020;52:1291-5. [PMID: 32683839 DOI: 10.4143/crt.2020.406] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Gracey E, Vereecke L, McGovern D, Fröhling M, Schett G, Danese S, De Vos M, Van den Bosch F, Elewaut D. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol 2020;16:415-33. [PMID: 32661321 DOI: 10.1038/s41584-020-0454-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
77 Reinisch W, Panaccione R, Bossuyt P, Baert F, Armuzzi A, Hébuterne X, Travis S, Danese S, Sandborn WJ, Schreiber S, Berg S, Zhou Q, Kligys K, Neimark E, Suleiman AA, D'Haens G, Colombel JF. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Inflamm Bowel Dis 2020;26:1562-71. [PMID: 32105310 DOI: 10.1093/ibd/izaa025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
78 Kumar A, Al-hassi HO, Steed H, Phipps O, Brookes MJ, Nakamura M. Bile Acids and the Microbiome: Making Sense of This Dynamic Relationship in Their Role and Management in Crohn’s Disease. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-12. [DOI: 10.1155/2022/8416578] [Reference Citation Analysis]
79 Levy AN, Allegretti JR. Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease. Therap Adv Gastroenterol 2019;12:1756284819836893. [PMID: 30906424 DOI: 10.1177/1756284819836893] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
80 Gökyer A, Küçükarda A, Sayın S, Keskin FEU, Çiçin İ. Stage I colon cancer that spreads into a colovesical fistula-mediated bladder due to crohn's disease: A case report. Current Problems in Cancer: Case Reports 2020;1:100010. [DOI: 10.1016/j.cpccr.2020.100010] [Reference Citation Analysis]
81 Seo JW, Kim ES, Han MH, Kweon YO. Non-cirrhotic portal hypertension related to azathioprine therapy in a patient with Crohn's disease. Intest Res 2021;19:247-51. [PMID: 32610890 DOI: 10.5217/ir.2020.00016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Bottoms L, Leighton D, Carpenter R, Anderson S, Langmead L, Ramage J, Faulkner J, Coleman E, Fairhurst C, Seed M, Tew G. Affective and enjoyment responses to 12 weeks of high intensity interval training and moderate continuous training in adults with Crohn's disease. PLoS One 2019;14:e0222060. [PMID: 31539378 DOI: 10.1371/journal.pone.0222060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Yang E, Shen J. The roles and functions of Paneth cells in Crohn's disease: A critical review. Cell Prolif 2021;54:e12958. [PMID: 33174662 DOI: 10.1111/cpr.12958] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
84 Battistini C, Ballan R, Herkenhoff ME, Saad SMI, Sun J. Vitamin D Modulates Intestinal Microbiota in Inflammatory Bowel Diseases. Int J Mol Sci 2020;22:E362. [PMID: 33396382 DOI: 10.3390/ijms22010362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
85 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:285-310. [PMID: 28670226 DOI: 10.5217/ir.2017.15.3.285] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
86 Csekő K, Beckers B, Keszthelyi D, Helyes Z. Role of TRPV1 and TRPA1 Ion Channels in Inflammatory Bowel Diseases: Potential Therapeutic Targets? Pharmaceuticals (Basel) 2019;12:E48. [PMID: 30935063 DOI: 10.3390/ph12020048] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
87 Cheng WX, Ren Y, Lu MM, Xu LL, Gao JG, Chen D, Kalyani FS, Lv ZY, Chen CX, Ji F, Lin HN, Jin X. Palmitoylation in Crohn’s disease: Current status and future directions. World J Gastroenterol 2021; 27(48): 8201-8215 [DOI: 10.3748/wjg.v27.i48.8201] [Reference Citation Analysis]
88 Bian D, Jiang Y, Gu Y, He Z, Chen Q, Tang Y, Zhong J, Shi Y. Body Mass Index and Disease Activity Are Associated With Moderate to Severe Disability in Crohn's Disease: A Cross-Sectional Study in Shanghai. Front Med (Lausanne) 2021;8:662488. [PMID: 34307398 DOI: 10.3389/fmed.2021.662488] [Reference Citation Analysis]
89 Wilkens R, Novak KL, Maaser C, Panaccione R, Kucharzik T. Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives. Therap Adv Gastroenterol 2021;14:17562848211006672. [PMID: 33948115 DOI: 10.1177/17562848211006672] [Reference Citation Analysis]
90 Popovic B, Varlot J, Hennequin J, Metzdorf PA, Jay N, Camenzind E, Bannay A. Outcomes after acute coronary syndrome in patients with inflammatory bowel disease. Heart Vessels. [DOI: 10.1007/s00380-022-02061-8] [Reference Citation Analysis]
91 Deng M, Hu J, Tong R, Guo H, Li X, Liu Y. miR-452-5p regulates the responsiveness of intestinal epithelial cells in inflammatory bowel disease through Mcl-1. Exp Ther Med 2021;22:813. [PMID: 34131436 DOI: 10.3892/etm.2021.10245] [Reference Citation Analysis]
92 Honap S, Johnston E, Agrawal G, Al-Hakim B, Hermon-Taylor J, Sanderson J. Anti-Mycobacterium paratuberculosis (MAP) therapy for Crohn's disease: an overview and update. Frontline Gastroenterol 2021;12:397-403. [PMID: 35401965 DOI: 10.1136/flgastro-2020-101471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
93 Wan J, Wang X, Zhang Y, Xue X, Li Y, Liu Z, Han S, Chen M, Nie Y, Shi Y, Liang J, Wu K. 5-Aminosalicylic Acid Prevents Disease Behavior Progression and Intestinal Resection in Colonic and Ileocolonic Crohn's Disease Patients: A Retrospective Study. Can J Gastroenterol Hepatol 2021;2021:1412663. [PMID: 34422708 DOI: 10.1155/2021/1412663] [Reference Citation Analysis]
94 Bao C, Wang D, Liu P, Shi Y, Jin X, Wu L, Zeng X, Zhang J, Liu H, Wu H. Effect of Electro-Acupuncture and Moxibustion on Brain Connectivity in Patients with Crohn's Disease: A Resting-State fMRI Study. Front Hum Neurosci 2017;11:559. [PMID: 29204113 DOI: 10.3389/fnhum.2017.00559] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
95 Elhenawy W, Oberc A, Coombes BK. A polymicrobial view of disease potential in Crohn's-associated adherent-invasive E. coli. Gut Microbes 2018;9:166-74. [PMID: 28914579 DOI: 10.1080/19490976.2017.1378291] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
96 Kantasiripitak W, Wang Z, Spriet I, Ferrante M, Dreesen E. Recent advancements in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases. Expert Rev Clin Pharmacol 2022. [PMID: 35034509 DOI: 10.1080/17512433.2021.2028619] [Reference Citation Analysis]
97 Alfredsson J, Wick MJ. Mechanism of fibrosis and stricture formation in Crohn's disease. Scand J Immunol 2020;92:e12990. [PMID: 33119150 DOI: 10.1111/sji.12990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
98 Wang JH, D’arcy M, Barnes EL, Freedman ND, Engels EA, Song M. Associations of Inflammatory Bowel Disease and Subsequent Cancers in a Population-Based Study of Older Adults in the United States. JNCI Cancer Spectrum 2022;6:pkab096. [DOI: 10.1093/jncics/pkab096] [Reference Citation Analysis]
99 Ungaro RC, Hu L, Ji J, Nayar S, Kugathasan S, Denson LA, Hyams J, Dubinsky MC, Sands BE, Cho JH. Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease. Aliment Pharmacol Ther 2021;53:281-90. [PMID: 33131065 DOI: 10.1111/apt.16136] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn's disease.Nat Rev Dis Primers. 2020;6:22. [PMID: 32242028 DOI: 10.1038/s41572-020-0156-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 23.5] [Reference Citation Analysis]
101 Shao BZ, Yao Y, Zhai JS, Zhu JH, Li JP, Wu K. The Role of Autophagy in Inflammatory Bowel Disease. Front Physiol 2021;12:621132. [PMID: 33633585 DOI: 10.3389/fphys.2021.621132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Viscido A, Capannolo A, Petroni R, Stefanelli G, Zerboni G, De Martinis M, Necozione S, Penco M, Frieri G, Latella G, Romano S. Association between Corrected QT Interval and C-Reactive Protein in Patients with Inflammatory Bowel Diseases. Medicina (Kaunas) 2020;56:E382. [PMID: 32751480 DOI: 10.3390/medicina56080382] [Reference Citation Analysis]
103 D'Amico F, Peyrin-Biroulet L, Danese S. Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic. J Clin Med 2020;9:E1536. [PMID: 32438763 DOI: 10.3390/jcm9051536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
104 Zhang J, Huang Q, Zhao R, Ma Z. A network pharmacology study on the Tripteryguim wilfordii Hook for treatment of Crohn's disease. BMC Complement Med Ther 2020;20:95. [PMID: 32293395 DOI: 10.1186/s12906-020-02885-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Rahman MM, Afroz S, Arthur S, Sundaram U. Mast Cell Mediated Regulation of Small Intestinal Chloride Malabsorption in SAMP1/YitFc Mouse Model of Spontaneous Chronic Ileitis. Cells 2021;10:697. [PMID: 33801010 DOI: 10.3390/cells10030697] [Reference Citation Analysis]
106 Nguyen NH, Kurnool S, Dulai PS, Boland BS, Sandborn WJ, Singh S. Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis. Inflamm Bowel Dis 2020;26:1429-35. [PMID: 31748806 DOI: 10.1093/ibd/izz276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Ge X, Tang S, Qi W, Liu W, Lv J, Cao Q, Zhou W, Cai X. Prevalence and predictors of surgical site infections after bowel resection for Crohn's disease: the role of dual-ring wound protector. Int J Colorectal Dis 2019;34:879-87. [PMID: 30868209 DOI: 10.1007/s00384-019-03275-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Eugenicos MP, Ferreira NB. Psychological factors associated with inflammatory bowel disease. Br Med Bull 2021;138:16-28. [PMID: 34057462 DOI: 10.1093/bmb/ldab010] [Reference Citation Analysis]
109 Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E, Badoglio M, Polge E, Labopin M, Gribben J, Pockley AG, Foulds GA, Lobo A, Travis S, Parkes M, Satsangi J, Papaioannou D, Lindsay JO; Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators., European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP). Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. BMC Gastroenterol 2019;19:82. [PMID: 31151436 DOI: 10.1186/s12876-019-0992-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
110 Vollenberg R, Tepasse P, Kühn JE, Hennies M, Strauss M, Rennebaum F, Schomacher T, Boeckel G, Lorentzen E, Bokemeyer A, Nowacki TM. Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2. Biomedicines 2022;10:171. [DOI: 10.3390/biomedicines10010171] [Reference Citation Analysis]
111 Shi L, Lu BL, Qiu Y, Huang L, Huang SY, Mao R, Lin JJ, Du JF, Feng ST, Li ZP, Sun CH, Li XH. Hepatic mosaic enhancement pattern correlates with increased inflammatory activity and adverse therapeutic outcomes in patients with Crohn's disease. Abdom Radiol (NY) 2021;46:3149-58. [PMID: 33646351 DOI: 10.1007/s00261-021-02979-z] [Reference Citation Analysis]
112 Ogundepo S, Chiamaka AM, Olatinwo M, Adepoju D, Aladesanmi MT, Celestine UO, Ali KC, Umezinwa OJ, Olasore J, Alausa A. The role of diosgenin in crohn’s disease. Clin Phytosci 2022;8. [DOI: 10.1186/s40816-022-00338-z] [Reference Citation Analysis]
113 Grandmougin A, D'Amico F, Remen T, Danese S, Bonneton M, Galloy MA, Peyrin-Biroulet L, Laurent V. Role of Cross-Sectional Imaging in Pediatric Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 34159487 DOI: 10.1007/s10620-021-07016-z] [Reference Citation Analysis]
114 Boumessid K, Barreau F, Mas E. How Can a Polymeric Formula Induce Remission in Crohn's Disease Patients? Int J Mol Sci 2021;22:4025. [PMID: 33919747 DOI: 10.3390/ijms22084025] [Reference Citation Analysis]
115 Sperger J, Shah KS, Lu M, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD, Kosorok MR. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients. medRxiv 2021:2021. [PMID: 33501455 DOI: 10.1101/2021.01.15.21249889] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Rogers KV, Martin SW, Bhattacharya I, Singh RSP, Nayak S. A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 - Model Framework. Clin Transl Sci 2021;14:239-48. [PMID: 32822108 DOI: 10.1111/cts.12849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Harris C, Cummings JRF. JAK1 inhibition and inflammatory bowel disease. Rheumatology (Oxford) 2021;60:ii45-51. [PMID: 33950226 DOI: 10.1093/rheumatology/keaa896] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Caio G, Lungaro L, Caputo F, Zoli E, Giancola F, Chiarioni G, De Giorgio R, Zoli G. Nutritional Treatment in Crohn's Disease. Nutrients 2021;13:1628. [PMID: 34066229 DOI: 10.3390/nu13051628] [Reference Citation Analysis]
119 Pak S, Hwang SW, Shim IK, Bae SM, Ryu YM, Kim HB, Do EJ, Son HN, Choi EJ, Park SH, Kim SY, Park SH, Ye BD, Yang SK, Kanai N, Maeda M, Okano T, Yang DH, Byeon JS, Myung SJ. Endoscopic Transplantation of Mesenchymal Stem Cell Sheets in Experimental Colitis in Rats. Sci Rep 2018;8:11314. [PMID: 30054522 DOI: 10.1038/s41598-018-29617-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
120 Schiff ER, Frampton M, Semplici F, Bloom SL, McCartney SA, Vega R, Lovat LB, Wood E, Hart AL, Crespi D, Furman MA, Mann S, Murray CD, Segal AW, Levine AP. A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population. Dig Dis Sci 2018;63:3049-57. [PMID: 30178286 DOI: 10.1007/s10620-018-5219-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
121 Zhang XY, Dong HC, Wang WF, Zhang Y. Risk of venous thromboembolism in children and adolescents with inflammatory bowel disease: A systematic review and meta-analysis. World J Gastroenterol 2022; 28(16): 1705-1717 [DOI: 10.3748/wjg.v28.i16.1705] [Reference Citation Analysis]
122 Lahat A, Veisman I. Capsule Endoscopy in Crohn's Disease-From a Relative Contraindication to Habitual Monitoring Tool. Diagnostics (Basel) 2021;11:1737. [PMID: 34679435 DOI: 10.3390/diagnostics11101737] [Reference Citation Analysis]
123 Rubbino F, Greco L, di Cristofaro A, Gaiani F, Vetrano S, Laghi L, Bonovas S, Piovani D. Journey through Crohn's Disease Complication: From Fistula Formation to Future Therapies. J Clin Med 2021;10:5548. [PMID: 34884247 DOI: 10.3390/jcm10235548] [Reference Citation Analysis]
124 Chateau T, Peyrin-Biroulet L. Evolving therapeutic goals in Crohn's disease management. United European Gastroenterol J 2020;8:133-9. [PMID: 32213074 DOI: 10.1177/2050640619887316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
125 Olaisen M, Flatberg A, Granlund AVB, Røyset ES, Martinsen TC, Sandvik AK, Fossmark R. Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn's Disease. Inflamm Bowel Dis 2021;27:12-24. [PMID: 32448900 DOI: 10.1093/ibd/izaa107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
126 Kurt S, Caron B, Gouynou C, Netter P, Vaizey CJ, Wexner SD, Danese S, Baumann C, Peyrin-Biroulet L. Faecal incontinence in inflammatory bowel disease: The Nancy experience. Dig Liver Dis 2022:S1590-8658(22)00136-0. [PMID: 35123908 DOI: 10.1016/j.dld.2022.01.125] [Reference Citation Analysis]
127 Yamazaki H, So R, Matsuoka K, Kobayashi T, Shinzaki S, Matsuura M, Okabayashi S, Kataoka Y, Tsujimoto Y, Furukawa TA, Watanabe N. Certolizumab pegol for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2019;8:CD012893. [PMID: 31476018 DOI: 10.1002/14651858.CD012893.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
128 Tepler A, Narula N, Peek RM Jr, Patel A, Edelson C, Colombel JF, Shah SC. Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:121-31. [PMID: 31165513 DOI: 10.1111/apt.15306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
129 Kong N, Gao C, Xu M, Gao X. Changes in the anterior cingulate cortex in Crohn's disease: A neuroimaging perspective. Brain Behav 2021;11:e02003. [PMID: 33314765 DOI: 10.1002/brb3.2003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Xing C, Zhang T, Liu X, Li C, Yang G, Zhang H, Wang R, Wang K, Miao Y, Lan D. Guanylin ligand protects the intestinal immune barrier by activating the guanylate cyclase-C signaling pathway. Acta Histochem 2021;124:151811. [PMID: 34920371 DOI: 10.1016/j.acthis.2021.151811] [Reference Citation Analysis]
131 Yu M, Wu H, Wang J, Chen X, Pan J, Liu P, Zhang J, Chen Y, Zhu W, Tang C, Jin Q, Li C, Lu C, Zeng H, Yu C, Sun J. Vitamin D receptor inhibits EMT via regulation of the epithelial mitochondrial function in intestinal fibrosis. J Biol Chem 2021;296:100531. [PMID: 33713706 DOI: 10.1016/j.jbc.2021.100531] [Reference Citation Analysis]
132 Chen P, Huang S, Yu Q, Chao K, Wang Y, Zhou G, Zhuang X, Zeng Z, Chen M, Zhang S. Serum exosomal microRNA-144-3p: a promising biomarker for monitoring Crohn's disease. Gastroenterology Report 2021. [DOI: 10.1093/gastro/goab056] [Reference Citation Analysis]
133 Tauzin AS, Pereira MR, Van Vliet LD, Colin PY, Laville E, Esque J, Laguerre S, Henrissat B, Terrapon N, Lombard V, Leclerc M, Doré J, Hollfelder F, Potocki-Veronese G. Investigating host-microbiome interactions by droplet based microfluidics. Microbiome 2020;8:141. [PMID: 33004077 DOI: 10.1186/s40168-020-00911-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
134 Kim ES. Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease. Gut Liver 2021;15:637-8. [PMID: 34521774 DOI: 10.5009/gnl210393] [Reference Citation Analysis]
135 Li J, Wang T, Kirtane AR, Shi Y, Jones A, Moussa Z, Lopes A, Collins J, Tamang SM, Hess K, Shakur R, Karandikar P, Lee JS, Huang HW, Hayward A, Traverso G. Gastrointestinal synthetic epithelial linings. Sci Transl Med 2020;12:eabc0441. [PMID: 32848090 DOI: 10.1126/scitranslmed.abc0441] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
136 Othman MO, Harb D, Barkin JA. Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician. Int J Clin Pract. 2018;72. [PMID: 29405509 DOI: 10.1111/ijcp.13066] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
137 Rencz F, Lakatos PL, Gulácsi L, Brodszky V, Kürti Z, Lovas S, Banai J, Herszényi L, Cserni T, Molnár T, Péntek M, Palatka K. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. Qual Life Res 2019;28:141-52. [PMID: 30225788 DOI: 10.1007/s11136-018-2003-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
138 Akiyama S, Lin A, Traboulsi C, Rubin DT. Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib. ACG Case Rep J 2021;8:e00690. [PMID: 34840997 DOI: 10.14309/crj.0000000000000690] [Reference Citation Analysis]
139 Kaplan GG, Bernstein CN, Coward S, Bitton A, Murthy SK, Nguyen GC, Lee K, Cooke-Lauder J, Benchimol EI. The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology. J Can Assoc Gastroenterol 2019;2:S6-S16. [PMID: 31294381 DOI: 10.1093/jcag/gwy054] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
140 Ślósarz D, Poniewierka E, Neubauer K, Kempiński R. Ultrasound Elastography in the Assessment of the Intestinal Changes in Inflammatory Bowel Disease-Systematic Review. J Clin Med 2021;10:4044. [PMID: 34575156 DOI: 10.3390/jcm10184044] [Reference Citation Analysis]
141 Yu M, Zhu W, Wang J, Chen X, He X, Lin B, Cen L, Zhou T, Lu C, Yu C, Sun J. Caveolin-1 Alleviates Crohn's Disease-induced Intestinal Fibrosis by Inhibiting Fibroblasts Autophagy Through Modulating Sequestosome 1. Inflamm Bowel Dis 2022:izab342. [PMID: 35020883 DOI: 10.1093/ibd/izab342] [Reference Citation Analysis]
142 Wu N, Chen D, Sun H, Tan J, Zhang Y, Zhang T, Han Y, Liu H, Ouyang X, Yang XD, Niu X, Zhong J, Wang Z, Su B. MAP3K2 augments Th1 cell differentiation via IL-18 to promote T cell-mediated colitis. Sci China Life Sci 2021;64:389-403. [PMID: 32737854 DOI: 10.1007/s11427-020-1720-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
143 Populin L, Stebbing MJ, Furness JB. Neuronal regulation of the gut immune system and neuromodulation for treating inflammatory bowel disease. FASEB Bioadv 2021;3:953-66. [PMID: 34761177 DOI: 10.1096/fba.2021-00070] [Reference Citation Analysis]
144 Voss J, Schneider CV, Kleinjans M, Bruns T, Trautwein C, Strnad P. Hepatobiliary phenotype of individuals with chronic intestinal disorders. Sci Rep 2021;11:19954. [PMID: 34620902 DOI: 10.1038/s41598-021-98843-7] [Reference Citation Analysis]
145 Monteleone G, Franzè E, Troncone E, Maresca C, Marafini I. Interleukin-34 Mediates Cross-Talk Between Stromal Cells and Immune Cells in the Gut. Front Immunol 2022;13:873332. [DOI: 10.3389/fimmu.2022.873332] [Reference Citation Analysis]
146 Merkley SD, Chock CJ, Yang XO, Harris J, Castillo EF. Modulating T Cell Responses via Autophagy: The Intrinsic Influence Controlling the Function of Both Antigen-Presenting Cells and T Cells. Front Immunol. 2018;9:2914. [PMID: 30619278 DOI: 10.3389/fimmu.2018.02914] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
147 Hu L, Liu F, Li L, Zhang L, Yan C, Li Q, Qiu J, Dong J, Sun J, Zhang H. Effects of icariin on cell injury and glucocorticoid resistance in BEAS-2B cells exposed to cigarette smoke extract. Exp Ther Med 2020;20:283-92. [PMID: 32550884 DOI: 10.3892/etm.2020.8702] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Saez A, Gomez-Bris R, Herrero-Fernandez B, Mingorance C, Rius C, Gonzalez-Granado JM. Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease. Int J Mol Sci 2021;22:7618. [PMID: 34299236 DOI: 10.3390/ijms22147618] [Reference Citation Analysis]
149 D'Amico F, Netter P, Baumann C, Veltin M, Zallot C, Aimone-Gastin I, Danese S, Peyrin-Biroulet L. Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. J Clin Med 2020;9:E2697. [PMID: 32825383 DOI: 10.3390/jcm9092697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
150 Labarile N, Ghosh S, Ng SC, Walters J, Iacucci M. Tests that now deserve to be more widely adopted in IBD clinical practice. Therap Adv Gastroenterol 2020;13:1756284820944088. [PMID: 32782481 DOI: 10.1177/1756284820944088] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Bakshi N, Hart AL, Lee MC, Williams ACC, Lackner JM, Norton C, Croft P. Chronic pain in patients with inflammatory bowel disease. Pain 2021;162:2466-71. [PMID: 34534174 DOI: 10.1097/j.pain.0000000000002304] [Reference Citation Analysis]
152 Chen H, Xu H, Luo L, Qiao L, Wang Y, Xu M, Li Y, Zhu P, Yang B. Thalidomide Prevented and Ameliorated Pathogenesis of Crohn's Disease in Mice via Regulation of Inflammatory Response and Fibrosis. Front Pharmacol 2019;10:1486. [PMID: 31920668 DOI: 10.3389/fphar.2019.01486] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
153 Ribaldone DG, Caviglia GP, Abdulle A, Pellicano R, Ditto MC, Morino M, Fusaro E, Saracco GM, Bugianesi E, Astegiano M. Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. J Clin Med 2019;8:E1646. [PMID: 31601034 DOI: 10.3390/jcm8101646] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
154 Huang Y, Yao D, Guo F, Zhou Z, Li Y. Preoperative Anti-TNF Therapy is Associated with a Shorter Length of Resected Bowel in Patients Undergoing Ileocolic Resection for Crohn's Disease. J Invest Surg 2022;:1-9. [PMID: 34983280 DOI: 10.1080/08941939.2021.2023713] [Reference Citation Analysis]
155 Krzystek-Korpacka M, Kempiński R, Bromke MA, Neubauer K. Oxidative Stress Markers in Inflammatory Bowel Diseases: Systematic Review. Diagnostics (Basel) 2020;10:E601. [PMID: 32824619 DOI: 10.3390/diagnostics10080601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
156 Bhurwal A, Minacapelli CD, Orosz E, Gupta K, Tait C, Dalal I, Zhang C, Zhao E, Rustgi VK. COVID-19 status quo: Emphasis on gastrointestinal and liver manifestations . World J Gastroenterol 2021; 27(46): 7969-7981 [DOI: 10.3748/wjg.v27.i46.7969] [Reference Citation Analysis]
157 Czepielewski RS, Erlich EC, Onufer EJ, Young S, Saunders BT, Han YH, Wohltmann M, Wang PL, Kim KW, Kumar S, Hsieh CS, Scallan JP, Yang Y, Zinselmeyer BH, Davis MJ, Randolph GJ. Ileitis-associated tertiary lymphoid organs arise at lymphatic valves and impede mesenteric lymph flow in response to tumor necrosis factor. Immunity 2021:S1074-7613(21)00409-X. [PMID: 34788601 DOI: 10.1016/j.immuni.2021.10.003] [Reference Citation Analysis]
158 Yao J, Jiang Y, Ke J, Lu Y, Hu J, Zhi M. A Validated Prognostic Model and Nomogram to Predict Early-Onset Complications Leading to Surgery in Patients With Crohn's Disease. Dis Colon Rectum 2021;64:697-705. [PMID: 33315712 DOI: 10.1097/DCR.0000000000001881] [Reference Citation Analysis]
159 Kyodo R, Takeuchi I, Narumi S, Shimizu H, Hata K, Yoshioka T, Tanase-nakao K, Shimizu T, Arai K. Novel biallelic mutations in the DUOX2 gene underlying very early-onset inflammatory bowel disease: A case report. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.109015] [Reference Citation Analysis]
160 Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1896-905. [PMID: 30934053 DOI: 10.1093/ibd/izz059] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
161 Park SK, Kim HN, Choi CH, Im JP, Cha JM, Eun CS, Kim TO, Kang SB, Bang KB, Kim HG, Jung Y, Yoon H, Han DS, Lee CW, Ahn K, Kim HL, Park DI. Differentially Abundant Bacterial Taxa Associated with Prognostic Variables of Crohn's Disease: Results from the IMPACT Study. J Clin Med 2020;9:E1748. [PMID: 32516912 DOI: 10.3390/jcm9061748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
162 Magalhães HIR, Castelucci P. Enteric nervous system and inflammatory bowel diseases: Correlated impacts and therapeutic approaches through the P2X7 receptor. World J Gastroenterol 2021; 27(46): 7909-7924 [DOI: 10.3748/wjg.v27.i46.7909] [Reference Citation Analysis]
163 Pobeguts OV, Ladygina VG, Evsyutina DV, Eremeev AV, Zubov AI, Matyushkina DS, Scherbakov PL, Rakitina DV, Fisunov GY. Propionate Induces Virulent Properties of Crohn's Disease-Associated Escherichia coli. Front Microbiol 2020;11:1460. [PMID: 32733408 DOI: 10.3389/fmicb.2020.01460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
164 Louis TJ, Qasem A, Naser SA. Attenuation of Excess TNF-α Release in Crohn’s Disease by Silencing of iRHOMs 1/2 and the Restoration of TGF-β Mediated Immunosuppression Through Modulation of TACE Trafficking. Front Immunol 2022;13:887830. [DOI: 10.3389/fimmu.2022.887830] [Reference Citation Analysis]
165 Leber A, Hontecillas R, Zoccoli-Rodriguez V, Bienert C, Chauhan J, Bassaganya-Riera J. Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. J Immunol 2019;203:3407-15. [PMID: 31694910 DOI: 10.4049/jimmunol.1900364] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
166 E Penna FGC, Rosa RM, da Cunha PFS, de Souza SCS, de Abreu Ferrari ML. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. BMC Gastroenterol. 2020;20:35. [PMID: 32054445 DOI: 10.1186/s12876-020-1183-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
167 Yin Y, Zhu ZX, Li Z, Chen YS, Zhu WM. Role of mesenteric component in Crohn’s disease: A friend or foe? World J Gastrointest Surg 2021; 13(12): 1536-1549 [DOI: 10.4240/wjgs.v13.i12.1536] [Reference Citation Analysis]
168 Orrell M, van 't Hullenaar C, Gosling J. Upper gastrointestinal tract involvement in Crohn's disease: A case report. Int J Surg Case Rep 2021;81:105810. [PMID: 33887830 DOI: 10.1016/j.ijscr.2021.105810] [Reference Citation Analysis]
169 Hong L, Chen G, Cai Z, Liu H, Zhang C, Wang F, Xiao Z, Zhong J, Wang L, Wang Z, Cui W. Balancing Microthrombosis and Inflammation via Injectable Protein Hydrogel for Inflammatory Bowel Disease. Adv Sci (Weinh) 2022;:e2200281. [PMID: 35524641 DOI: 10.1002/advs.202200281] [Reference Citation Analysis]
170 Yan Y, Xing C, Xiao Y, Shen X, Zhang Z, He C, Shi JB, Liu M, Liu X. Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8 Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease In Vivo. J Med Chem 2022. [PMID: 35536548 DOI: 10.1021/acs.jmedchem.2c00356] [Reference Citation Analysis]
171 Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A. Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci 2017;18:E1973. [PMID: 28906475 DOI: 10.3390/ijms18091973] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
172 Liu XH, Wu XR, Lan N, Zheng XB, Zhou C, Hu T, Chen YF, Cai ZR, Chen ZX, Lan P, Wu XJ. CD73 promotes colitis-associated tumorigenesis in mice. Oncol Lett 2020;20:1221-30. [PMID: 32724362 DOI: 10.3892/ol.2020.11670] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
173 Wark G, Samocha-Bonet D, Ghaly S, Danta M. The Role of Diet in the Pathogenesis and Management of Inflammatory Bowel Disease: A Review. Nutrients 2020;13:E135. [PMID: 33396537 DOI: 10.3390/nu13010135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
174 Lee C, Hong SN, Kim ER, Chang DK, Kim YH. Epithelial Regeneration Ability of Crohn's Disease Assessed Using Patient-Derived Intestinal Organoids. Int J Mol Sci 2021;22:6013. [PMID: 34199463 DOI: 10.3390/ijms22116013] [Reference Citation Analysis]
175 Reikvam H, Tvedt T, Johansen S, Aase Setran H, Havre R. Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation. Transplantology 2020;1:102-10. [DOI: 10.3390/transplantology1020010] [Reference Citation Analysis]
176 Xie Y, Chen J, Wu B, He T, Xie L, Liu Z. Dock2 affects the host susceptibility to Citrobacter rodentium infection through regulating gut microbiota. Gut Pathog 2021;13:52. [PMID: 34391464 DOI: 10.1186/s13099-021-00449-x] [Reference Citation Analysis]
177 Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020;9. [PMID: 32047622 DOI: 10.12688/f1000research.20928.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
178 Chen X, Wang D, Zheng F, Zhu L, Huang Y, Zhu Y, Huang Y, Xu H, Li Z. Effects of Posaconazole on Tacrolimus Population Pharmacokinetics and Initial Dose in Children With Crohn’s Disease Undergoing Hematopoietic Stem Cell Transplantation. Front Pharmacol 2022;13:758524. [DOI: 10.3389/fphar.2022.758524] [Reference Citation Analysis]
179 Snyder EF, Davis S, Aldrich K, Veerabagu M, Larussa T, Abenavoli L, Boccuto L. Crohn disease: Identification, diagnosis, and clinical management. Nurse Pract 2021;46:22-30. [PMID: 34808643 DOI: 10.1097/01.NPR.0000798212.61425.4f] [Reference Citation Analysis]
180 Antunes JC, Seabra CL, Domingues JM, Teixeira MO, Nunes C, Costa-Lima SA, Homem NC, Reis S, Amorim MTP, Felgueiras HP. Drug Targeting of Inflammatory Bowel Diseases by Biomolecules. Nanomaterials (Basel) 2021;11:2035. [PMID: 34443866 DOI: 10.3390/nano11082035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
181 Tepasse PR, Vollenberg R, Nowacki TM. Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand? Life (Basel) 2021;11:1220. [PMID: 34833096 DOI: 10.3390/life11111220] [Reference Citation Analysis]
182 Li L, Ma J, Xu JG, Zheng YL, Xie Q, Rong L, Liang ZH. Brain functional changes in patients with Crohn's disease: A resting-state fMRI study. Brain Behav 2021;11:e2243. [PMID: 34124857 DOI: 10.1002/brb3.2243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Otten AT, Bourgonje AR, Peters V, Alizadeh BZ, Dijkstra G, Harmsen HJM. Vitamin C Supplementation in Healthy Individuals Leads to Shifts of Bacterial Populations in the Gut-A Pilot Study. Antioxidants (Basel) 2021;10:1278. [PMID: 34439526 DOI: 10.3390/antiox10081278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Roberts KJ, Cubitt MF, Carlton TM, Rodrigues-Duarte L, Maggiore L, Chai R, Clare S, Harcourt K, MacDonald TT, Ray KP, Vossenkämper A, West MR, Crowe JS. Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Sci Rep 2021;11:19422. [PMID: 34593832 DOI: 10.1038/s41598-021-97236-0] [Reference Citation Analysis]
185 Chen S, Liu H, Li Z, Tang J, Huang B, Zhi F, Zhao X. Epithelial PBLD attenuates intestinal inflammatory response and improves intestinal barrier function by inhibiting NF-κB signaling. Cell Death Dis 2021;12:563. [PMID: 34059646 DOI: 10.1038/s41419-021-03843-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Babiker AM, Alkharraz AHA, Yusef Alsaeed HA, Aldubaiyan AAR. Mild Abdominal Trauma Complicated With Bowel Perforation in Patient With Crohn’s Disease: Clinical and Intraoperative Findings. Cureus. [DOI: 10.7759/cureus.21977] [Reference Citation Analysis]
187 Bertani L, Barberio B, Tricò D, Zanzi F, Maniero D, Ceccarelli L, Marsilio I, Coppini F, Lorenzon G, Mumolo MG, Zingone F, Costa F, Savarino EV. Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak. J Clin Med 2021;10:3270. [PMID: 34362053 DOI: 10.3390/jcm10153270] [Reference Citation Analysis]
188 de Sire R, Nardone OM, Testa A, Calabrese G, Caiazzo A, Castiglione F. Exclusive Enteral Nutrition in Adult Crohn's Disease: an Overview of Clinical Practice and Perceived Barriers. Clin Exp Gastroenterol 2021;14:493-501. [PMID: 35002274 DOI: 10.2147/CEG.S267172] [Reference Citation Analysis]
189 Nishikawa H, Nakamura S, Miyazaki T, Kakimoto K, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Inflammatory Bowel Disease and Sarcopenia: Its Mechanism and Clinical Importance. J Clin Med 2021;10:4214. [PMID: 34575326 DOI: 10.3390/jcm10184214] [Reference Citation Analysis]
190 Scarallo L, Lionetti P. Dietary Management in Pediatric Patients with Crohn's Disease. Nutrients 2021;13:1611. [PMID: 34064976 DOI: 10.3390/nu13051611] [Reference Citation Analysis]
191 Blander JM. On cell death in the intestinal epithelium and its impact on gut homeostasis. Curr Opin Gastroenterol 2018;34:413-9. [PMID: 30169459 DOI: 10.1097/MOG.0000000000000481] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
192 Zheng XB, He XW, Zhang LJ, Qin HB, Lin XT, Liu XH, Zhou C, Liu HS, Hu T, Cheng HC, He XS, Wu XR, Chen YF, Ke J, Wu XJ, Lan P. Bone marrow-derived CXCR4-overexpressing MSCs display increased homing to intestine and ameliorate colitis-associated tumorigenesis in mice. Gastroenterol Rep (Oxf) 2019;7:127-38. [PMID: 30976426 DOI: 10.1093/gastro/goy017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
193 Wang X, Xie L, Long J, Liu K, Lu J, Liang Y, Cao Y, Dai X, Li X. Therapeutic effect of baicalin on inflammatory bowel disease: A review. J Ethnopharmacol 2022;283:114749. [PMID: 34666140 DOI: 10.1016/j.jep.2021.114749] [Reference Citation Analysis]
194 Luceri C, Bigagli E, Agostiniani S, Giudici F, Zambonin D, Scaringi S, Ficari F, Lodovici M, Malentacchi C. Analysis of Oxidative Stress-Related Markers in Crohn's Disease Patients at Surgery and Correlations with Clinical Findings. Antioxidants (Basel) 2019;8:E378. [PMID: 31489956 DOI: 10.3390/antiox8090378] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
195 Graffigna G, Bosio C, Pagnini F, Volpato E, Previtali E, Leone S, D'Amico F, Armuzzi A, Danese S. Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement. BMC Psychol 2021;9:186. [PMID: 34839834 DOI: 10.1186/s40359-021-00692-6] [Reference Citation Analysis]
196 González-Serna D, Ochoa E, López-Isac E, Julià A, Degenhardt F, Ortego-Centeno N, Radstake TRDJ, Franke A, Marsal S, Mayes MD, Martín J, Márquez A; Scleroderma Genetic Consortium. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn's disease. Sci Rep 2020;10:1862. [PMID: 32024964 DOI: 10.1038/s41598-020-58741-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
197 Chen G, Lissoos T, Dieyi C, Null KD. Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study. Inflamm Bowel Dis 2021;27:1177-83. [PMID: 33043982 DOI: 10.1093/ibd/izaa263] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
198 Stanisic D, Jeremic N, Majumder S, Pushpakumar S, George A, Singh M, Tyagi SC. High Fat Diet Dysbiotic Mechanism of Decreased Gingival Blood Flow. Front Physiol 2021;12:625780. [PMID: 33746772 DOI: 10.3389/fphys.2021.625780] [Reference Citation Analysis]
199 Hugot JP, Dumay A, Barreau F, Meinzer U. Crohn's Disease: Is the Cold Chain Hypothesis Still Hot? J Crohns Colitis 2021;15:678-86. [PMID: 32949122 DOI: 10.1093/ecco-jcc/jjaa192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Heriot A, Smart P. Current Status of Segmental Colectomy in Select Crohn's Disease Patients. Clin Colon Rectal Surg 2019;32:249-54. [PMID: 31275070 DOI: 10.1055/s-0039-1683906] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
201 Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12:e0185500. [PMID: 28973005 DOI: 10.1371/journal.pone.0185500] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 11.2] [Reference Citation Analysis]
202 Gao W, Zhang T, Wu H. Emerging Pathological Engagement of Ferroptosis in Gut Diseases. Oxid Med Cell Longev 2021;2021:4246255. [PMID: 34733403 DOI: 10.1155/2021/4246255] [Reference Citation Analysis]
203 Voina-tonea A, Labunet A, Objelean A, Onisor F, Bran S, Mester A, Piciu A, Sava S. A Systematic Analysis of the Available Human Clinical Studies of Dental Implant Failure in Patients with Inflammatory Bowel Disease. Medicina 2022;58:343. [DOI: 10.3390/medicina58030343] [Reference Citation Analysis]
204 Soontararak S, Chow L, Johnson V, Coy J, Wheat W, Regan D, Dow S. Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease Model. Stem Cells Transl Med 2018;7:456-67. [PMID: 29635868 DOI: 10.1002/sctm.17-0305] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 11.3] [Reference Citation Analysis]
205 Losurdo G, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C. Diagnostics (Basel). 2020;10. [PMID: 33276638 DOI: 10.3390/diagnostics10121037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
206 Agrawal M, Petralia F, Tepler A, Durbin L, Reinisch W, Colombel JF, Shah SC. Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials. Inflamm Bowel Dis 2022:izac067. [PMID: 35366313 DOI: 10.1093/ibd/izac067] [Reference Citation Analysis]
207 Atreya R. Endoscopy as a Diagnostic Tool for Personalized Therapy in IBD: Prediction of Response to Biological Therapy. Drug Res (Stuttg) 2021;71:S3-4. [PMID: 34788874 DOI: 10.1055/a-1606-4913] [Reference Citation Analysis]
208 le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology 2022:S0016-5085(21)04067-1. [PMID: 34995529 DOI: 10.1053/j.gastro.2021.09.076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
209 Smits LJT, Pauwels RWM, Kievit W, de Jong DJ, de Vries AC, Hoentjen F, van der Woude CJ; LADI study group. Lengthening adalimumab dosing interval in quiescent Crohn's disease patients: protocol for the pragmatic randomised non-inferiority LADI study. BMJ Open 2020;10:e035326. [PMID: 32461297 DOI: 10.1136/bmjopen-2019-035326] [Reference Citation Analysis]
210 Irak K, Bayram M, Cifci S, Sener G. Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn's disease. PLoS One 2021;16:e0260034. [PMID: 34788319 DOI: 10.1371/journal.pone.0260034] [Reference Citation Analysis]
211 Hirten RP, Ungaro RC, Castaneda D, Lopatin S, Sands BE, Colombel JF, Cohen BL. Anastomotic Ulcers After Ileocolic Resection for Crohn's Disease Are Common and Predict Recurrence. Inflamm Bowel Dis 2020;26:1050-8. [PMID: 31639193 DOI: 10.1093/ibd/izz224] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
212 Matsunaga Y, Hasei S, Yamamotoya T, Honda H, Kushiyama A, Sakoda H, Fujishiro M, Ono H, Ito H, Okabe T, Asano T, Nakatsu Y. Pathological Role of Pin1 in the Development of DSS-Induced Colitis. Cells 2021;10:1230. [PMID: 34067858 DOI: 10.3390/cells10051230] [Reference Citation Analysis]
213 Barros LL, Farias AQ, Rezaie A. Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment. World J Gastroenterol 2019; 25(31): 4414-4426 [PMID: 31496621 DOI: 10.3748/wjg.v25.i31.4414] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
214 Snell A, Segal J, Limdi J, Banerjee R. Inflammatory bowel disease in India: challenges and opportunities. Frontline Gastroenterol 2021;12:390-6. [DOI: 10.1136/flgastro-2020-101500] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
215 Chang J, Li CC, Achtari M, Stoufi E. Crohn's disease initiated with extraintestinal features. BMJ Case Rep 2019;12:e229916. [PMID: 31005876 DOI: 10.1136/bcr-2019-229916] [Reference Citation Analysis]
216 Iwata K, Mikami Y, Kato M, Yahagi N, Kanai T. Pathogenesis and management of gastrointestinal inflammation and fibrosis: from inflammatory bowel diseases to endoscopic surgery. Inflamm Regen 2021;41:21. [PMID: 34261521 DOI: 10.1186/s41232-021-00174-7] [Reference Citation Analysis]
217 Cluny NL, Nyuyki KD, Almishri W, Griffin L, Lee BH, Hirota SA, Pittman QJ, Swain MG, Sharkey KA. Recruitment of α4β7 monocytes and neutrophils to the brain in experimental colitis is associated with elevated cytokines and anxiety-like behavior. J Neuroinflammation 2022;19:73. [PMID: 35379260 DOI: 10.1186/s12974-022-02431-z] [Reference Citation Analysis]
218 Bouland GA, Beulens JWJ, Nap J, van der Slik AR, Zaldumbide A, 't Hart LM, Slieker RC. CONQUER: an interactive toolbox to understand functional consequences of GWAS hits. NAR Genom Bioinform 2020;2:lqaa085. [PMID: 33575630 DOI: 10.1093/nargab/lqaa085] [Reference Citation Analysis]
219 Lasa J, Correa G, Fuxman C, Garbi L, Linares ME, Lubrano P, Rausch A, Toro M, Yantorno M, Zubiaurre I, Peyrin-Biroulet L, Olivera P. Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study. Gastroenterol Res Pract 2020;2020:4060648. [PMID: 32411197 DOI: 10.1155/2020/4060648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
220 Okuno H, Ogino H, Ihara E, Nishioka K, Tanaka Y, Chinen T, Kohjima M, Oono T, Tanaka M, Goya T, Fujimori N, Iboshi Y, Gotoda T, Ogawa Y. Discriminant equation using mucosally expressed cytokines and transcription factor for making definite diagnosis of inflammatory bowel disease unclassified. BMC Gastroenterol 2021;21:73. [PMID: 33593285 DOI: 10.1186/s12876-021-01656-1] [Reference Citation Analysis]
221 Di Ruscio M, Lunardi G, Buonfrate D, Gobbi F, Bertoli G, Piccoli D, Conti A, Geccherle A, Variola A. A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy. Medicina (Kaunas) 2021;57:1048. [PMID: 34684085 DOI: 10.3390/medicina57101048] [Reference Citation Analysis]
222 Soliman M, Shirazi-Nejad A, Bullas D, Said E. An Unusual Case of Pyrexia of Unknown Origin. Cureus 2021;13:e16684. [PMID: 34513347 DOI: 10.7759/cureus.16684] [Reference Citation Analysis]
223 D'Amico F, Chateau T, Laurent V, Danese S, Peyrin-Biroulet L. Which MRI Score and Technique Should Be Used for Assessing Crohn's Disease Activity? J Clin Med 2020;9:E1691. [PMID: 32498279 DOI: 10.3390/jcm9061691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
224 Boyd M, Thodberg M, Vitezic M, Bornholdt J, Vitting-Seerup K, Chen Y, Coskun M, Li Y, Lo BZS, Klausen P, Jan Schweiger P, Pedersen AG, Rapin N, Skovgaard K, Dahlgaard K, Andersson R, Terkelsen TB, Lilje B, Troelsen JT, Petersen AM, Jensen KB, Gögenur I, Thielsen P, Seidelin JB, Nielsen OH, Bjerrum JT, Sandelin A. Characterization of the enhancer and promoter landscape of inflammatory bowel disease from human colon biopsies. Nat Commun 2018;9:1661. [PMID: 29695774 DOI: 10.1038/s41467-018-03766-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
225 Wang Y, Miller M, Astrakhan Y, Petersen BS, Schreiber S, Franke A, Bromberg Y. Identifying Crohn's disease signal from variome analysis. Genome Med. 2019;11:59. [PMID: 31564248 DOI: 10.1186/s13073-019-0670-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
226 Stanzione A, Boccadifuoco F, Cuocolo R, Romeo V, Mainenti PP, Brunetti A, Maurea S. State of the art in abdominal MRI structured reporting: a review. Abdom Radiol (NY) 2021;46:1218-28. [PMID: 32936418 DOI: 10.1007/s00261-020-02744-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
227 Wynne J, Kozuch P. Medical marijuana for inflammatory bowel disease: the highs and lows. Scand J Gastroenterol 2021;:1-9. [PMID: 34919496 DOI: 10.1080/00365521.2021.1998604] [Reference Citation Analysis]
228 Friedrich M, Pohin M, Jackson MA, Korsunsky I, Bullers SJ, Rue-Albrecht K, Christoforidou Z, Sathananthan D, Thomas T, Ravindran R, Tandon R, Peres RS, Sharpe H, Wei K, Watts GFM, Mann EH, Geremia A, Attar M, McCuaig S, Thomas L, Collantes E, Uhlig HH, Sansom SN, Easton A, Raychaudhuri S, Travis SP, Powrie FM; Oxford IBD Cohort Investigators., Roche Fibroblast Network Consortium. IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nat Med 2021;27:1970-81. [PMID: 34675383 DOI: 10.1038/s41591-021-01520-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
229 Yilmaz H. Young age and shorter duration of Crohn's disease are associated with non-adherence to taking medication. North Clin Istanb 2022;9:8-13. [PMID: 35340313 DOI: 10.14744/nci.2021.08634] [Reference Citation Analysis]
230 Jefremow A, Neurath MF. New agents for immunosuppression. Best Pract Res Clin Gastroenterol 2021;54-55:101763. [PMID: 34874846 DOI: 10.1016/j.bpg.2021.101763] [Reference Citation Analysis]
231 Aguiar Zdovc J, Hanžel J, Kurent T, Sever N, Koželj M, Smrekar N, Novak G, Štabuc B, Dreesen E, Thomas D, Vovk T, Ostanek B, Drobne D, Grabnar I. Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. Pharmaceutics 2021;13:1587. [PMID: 34683880 DOI: 10.3390/pharmaceutics13101587] [Reference Citation Analysis]
232 Al Khoury A, Xiao Y, Golovics PA, Kohen R, Afif W, Wild G, Friedman G, Galiatsatos P, Hilzenrat N, Szilagyi A, Wyse J, Cohen A, Bitton A, Bessissow T, Lakatos PL. Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort. Dig Liver Dis 2021;53:980-6. [PMID: 33640302 DOI: 10.1016/j.dld.2021.02.006] [Reference Citation Analysis]
233 Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V, Ali SA, Allez M, Ananthakrishnan AN, Bhattacharya A, Dubinsky M, Griffiths A, Hart A, Korelitz B, Kotze PG, Koutroubakis IE, Lakatos PL, Lindsay JO, Magro F, Mantzaris GJ, Ng SC, O'morain C, Panés J, Parigi T, Ran Z, Rogler G, Rubin DT, Sachar DB, Siegmund B, Steinwurz F, Tysk C, Vavricka S, Verstraete SG, Brezin AP, Haemel AK, Dignass A, Sands BE, Danese S, Peyrin-biroulet L. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00297-1] [Reference Citation Analysis]
234 Rozendorn N, Amitai MM, Eliakim RA, Kopylov U, Klang E. A review of magnetic resonance enterography-based indices for quantification of Crohn's disease inflammation. Therap Adv Gastroenterol 2018;11:1756284818765956. [PMID: 29686731 DOI: 10.1177/1756284818765956] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
235 Sun QH, Wang YS, Liu G, Zhou HL, Jian YP, Liu MD, Zhang D, Ding Q, Zhao RX, Chen JF, Li YN, Liang J, Li YL, Quan CS, Xu ZX. Enhanced O-linked Glcnacylation in Crohn's disease promotes intestinal inflammation. EBioMedicine 2020;53:102693. [PMID: 32114385 DOI: 10.1016/j.ebiom.2020.102693] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
236 Shen JL, Zhou Z, Cao JS, Zhang B, Hu JH, Li JY, Liu XM, Juengpanich S, Li MS, Feng X. Biologic therapy for Crohn’s disease over the last 3 decades. World J Clin Cases 2022; 10(2): 594-606 [DOI: 10.12998/wjcc.v10.i2.594] [Reference Citation Analysis]
237 Liu Z, Ying Y. The Inhibitory Effect of Curcumin on Virus-Induced Cytokine Storm and Its Potential Use in the Associated Severe Pneumonia. Front Cell Dev Biol 2020;8:479. [PMID: 32596244 DOI: 10.3389/fcell.2020.00479] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 20.5] [Reference Citation Analysis]
238 Chen H, Chen C, Yuan X, Xu W, Yang MQ, Li Q, Shen Z, Yin L. Identification of Immune Cell Landscape and Construction of a Novel Diagnostic Nomogram for Crohn's Disease. Front Genet 2020;11:423. [PMID: 32425988 DOI: 10.3389/fgene.2020.00423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
239 Dong X, Tang S, Liu W, Qi W, Ye L, Yang X, Ge X, Zhou W. Prognostic significance of the Controlling Nutritional Status (CONUT) score in predicting postoperative complications in patients with Crohn's disease. Sci Rep 2020;10:19040. [PMID: 33149221 DOI: 10.1038/s41598-020-76115-0] [Reference Citation Analysis]
240 Gomolin A, Zargham H, Sant'Anna AM, Lovett A. Vulvar swelling and the timely diagnosis of Crohn's disease: A case report. SAGE Open Med Case Rep 2021;9:2050313X211008627. [PMID: 33889413 DOI: 10.1177/2050313X211008627] [Reference Citation Analysis]
241 Pavlidis S, Monast C, Loza MJ, Branigan P, Chung KF, Adcock IM, Guo Y, Rowe A, Baribaud F. I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment. PLoS Comput Biol 2019;15:e1006951. [PMID: 31039157 DOI: 10.1371/journal.pcbi.1006951] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
242 Niu W, Yang F, Fu Z, Dong Y, Zhang Z, Ju J. The role of enteric dysbacteriosis and modulation of gut microbiota in the treatment of inflammatory bowel disease. Microb Pathog 2021;:105381. [PMID: 34974123 DOI: 10.1016/j.micpath.2021.105381] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Park J, Lee JW, Cooper SC, Broxmeyer HE, Cannon JR, Kim CH. Parkinson disease-associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response. J Leukoc Biol 2017;102:1093-102. [PMID: 28751472 DOI: 10.1189/jlb.1A0417-147RR] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
244 Feagan BG, Schwartz D, Danese S, Rubin DT, Lissoos TW, Xu J, Lasch K. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018;12:621-626. [PMID: 29471381 DOI: 10.1093/ecco-jcc/jjy019] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
245 Wang YB, Jiang GH, Zhang Z, Li-YingCui, Liu ST, Zhang WH, Gong JF, Duan M, Yi-Li, Ji Q. A nomogram to predict prolonged postoperative ileus after intestinal resection for Crohn's disease. Int J Colorectal Dis 2022. [PMID: 35315507 DOI: 10.1007/s00384-022-04134-6] [Reference Citation Analysis]
246 Luo W, Shen Z, Deng M, Li X, Tan B, Xiao M, Wu S, Yang Z, Zhu C, Tian L, Wu X, Meng X, Quan Y, Wang X. Roseburia intestinalis supernatant ameliorates colitis induced in mice by regulating the immune response. Mol Med Rep 2019;20:1007-16. [PMID: 31173202 DOI: 10.3892/mmr.2019.10327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
247 Golusda L, Kühl AA, Siegmund B, Paclik D. Reducing Pain in Experimental Models of Intestinal Inflammation Affects the Immune Response. Inflamm Bowel Dis 2021:izab290. [PMID: 34871378 DOI: 10.1093/ibd/izab290] [Reference Citation Analysis]
248 Wang SY, Zhao JM, Zhou CL, Zheng HD, Huang Y, Zhao M, Zhang ZY, Wu LY, Wu HG, Liu HR. Herbal cake-partitioned moxibustion inhibits colonic autophagy in Crohn’s disease via signaling involving distinct classes of phosphatidylinositol 3-kinases. World J Gastroenterol 2020; 26(39): 5997-6014 [PMID: 33132650 DOI: 10.3748/wjg.v26.i39.5997] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
249 Curciarello R, Sobande T, Jones S, Giuffrida P, Di Sabatino A, Docena GH, MacDonald TT, Kok K. Human Neutrophil Elastase Proteolytic Activity in Ulcerative Colitis Favors the Loss of Function of Therapeutic Monoclonal Antibodies. J Inflamm Res 2020;13:233-43. [PMID: 32547155 DOI: 10.2147/JIR.S234710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
250 Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs 2019;79:1321-35. [PMID: 31317509 DOI: 10.1007/s40265-019-01169-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
251 Fermon C, Gerfaud-Valentin M, Durupt F, Sève P. Aphthous Stomatitis in a Man with Psoriatic Arthritis. Am J Med 2021;134:749-50. [PMID: 33607089 DOI: 10.1016/j.amjmed.2021.01.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
252 Mokros Ł, Domżał-Magrowska D, Pietras T, Sipowicz K, Talar-Wojnarowska R. The Association between Temperament, Chronotype, Depressive Symptoms, and Disease Activity among Patients with Inflammatory Bowel Disease-A Cross-Sectional Pilot Study. Life (Basel) 2021;11:1347. [PMID: 34947878 DOI: 10.3390/life11121347] [Reference Citation Analysis]
253 Zhou T, Sheng Y, Guan H. Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China. Adv Ther 2021;38:4233-45. [PMID: 34089502 DOI: 10.1007/s12325-021-01806-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Ali AS, Alhothali OS, Hammoudah AA, Kh Alsaede A, Alraddadi AA. Multidrug Resistance and Flaring up of Manifestation in Fistulizing Crohn's Disease after Surgery on a Perianal Lesion. Case Rep Gastroenterol 2021;15:626-31. [PMID: 34616267 DOI: 10.1159/000515611] [Reference Citation Analysis]
255 Mehrtash F. Sustained Crohn’s Disease Remission with an Exclusive Elemental and Exclusion Diet: A Case Report. GastrointestDisord 2021;3:129-38. [DOI: 10.3390/gidisord3030014] [Reference Citation Analysis]
256 Uzzan M, Tokuyama M, Rosenstein AK, Tomescu C, SahBandar IN, Ko HM, Leyre L, Chokola A, Kaplan-Lewis E, Rodriguez G, Seki A, Corley MJ, Aberg J, La Porte A, Park EY, Ueno H, Oikonomou I, Doron I, Iliev ID, Chen BK, Lui J, Schacker TW, Furtado GC, Lira SA, Colombel JF, Horowitz A, Lim JK, Chomont N, Rahman AH, Montaner LJ, Ndhlovu LC, Mehandru S. Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals. Sci Transl Med 2018;10:eaau4711. [PMID: 30282696 DOI: 10.1126/scitranslmed.aau4711] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
257 Kimura K, Yoshida A, Katagiri F, Takayanagi R, Yamada Y. Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling. Biopharm Drug Dispos 2019;40:250-61. [PMID: 31256430 DOI: 10.1002/bdd.2198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D'Haens GR. Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Gut 2020;69:658-64. [PMID: 31285357 DOI: 10.1136/gutjnl-2019-318256] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
259 Schreiber S, Irving PM, Sharara AI, Martín-Arranz MD, Hébuterne X, Penchev P, Danese S, Anthopoulos P, Akhundova-Unadkat G, Baert F. Review: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions. Aliment Pharmacol Ther 2022. [PMID: 35132657 DOI: 10.1111/apt.16781] [Reference Citation Analysis]
260 Dulai PS, Osterman MT, Lasch K, Cao C, Riaz F, Sandborn WJ. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. Dig Dis Sci 2019;64:2478-88. [PMID: 30923985 DOI: 10.1007/s10620-019-05594-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
261 Zielinski MR, Systrom DM, Rose NR. Fatigue, Sleep, and Autoimmune and Related Disorders. Front Immunol 2019;10:1827. [PMID: 31447842 DOI: 10.3389/fimmu.2019.01827] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
262 Wilkens R, Dolinger M, Burisch J, Maaser C. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology 2022:S0016-5085(21)04072-5. [PMID: 34995530 DOI: 10.1053/j.gastro.2021.10.052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
263 Xiao-qing D, Xiao-ying L, Xue-jun W, Xiao-cong G, Jun-yi L, Yun-qiong L, Li L, Jia-ni C, Dan Z, Yuan L, Huan-gan W, Chen X, Xiao-peng M. Study on the regulatory effect of herbal cake-partitioned moxibustion on colonic CD206, AMPK and TSC2 in rats with Crohn disease. J Acupunct Tuina Sci 2021;19:329-37. [DOI: 10.1007/s11726-021-1263-7] [Reference Citation Analysis]
264 Trefzer R, Elpeleg O, Gabrusskaya T, Stepensky P, Mor-Shaked H, Grosse R, Brandt DT. Characterization of a L136P mutation in Formin-like 2 (FMNL2) from a patient with chronic inflammatory bowel disease. PLoS One 2021;16:e0252428. [PMID: 34043722 DOI: 10.1371/journal.pone.0252428] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
265 Peng L, Gao X, Nie L, Xie J, Dai T, Shi C, Tao L, Wang Y, Tian Y, Sheng J. Astragalin Attenuates Dextran Sulfate Sodium (DSS)-Induced Acute Experimental Colitis by Alleviating Gut Microbiota Dysbiosis and Inhibiting NF-κB Activation in Mice. Front Immunol 2020;11:2058. [PMID: 33042117 DOI: 10.3389/fimmu.2020.02058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
266 D'Arcangelo G, Abi Nader E, Charbit-Henrion F, Talbotec C, Goulet O, Ruemmele FM, Pigneur B. Increased Use of Anti-Tumor Necrosis Factor Following the Implementation of the ECCO-ESPGHAN Guidelines and its Impact on the Outcome of Pediatric Crohn's Disease: A Retrospective Single-Center Study. J Pediatr Gastroenterol Nutr 2022;74:79-84. [PMID: 34962501 DOI: 10.1097/MPG.0000000000003301] [Reference Citation Analysis]
267 Sun XL, Qiao LC, Gong J, Wen K, Xu ZZ, Yang BL. Proteomics identifies a novel role of fibrinogen-like protein 1 in Crohn’s disease. World J Gastroenterol 2021; 27(35): 5946-5957 [PMID: 34629811 DOI: 10.3748/wjg.v27.i35.5946] [Reference Citation Analysis]
268 Oshima S, Watanabe M. Genetic and environmental factors drive personalized medicine for Crohn's disease. J Clin Invest 2018;128:4758-60. [PMID: 30320603 DOI: 10.1172/JCI124303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
269 Gordon IO, Bettenworth D, Bokemeyer A, Srivastava A, Rosty C, de Hertogh G, Robert ME, Valasek MA, Mao R, Kurada S, Harpaz N, Borralho P, Pai RK, Pai RK, Odze R, Feakins R, Parker CE, Nguyen T, Jairath V, Baker ME, Bruining DH, Fletcher JG, Feagan BG, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review. Gastroenterology 2020;158:137-150.e1. [PMID: 31476299 DOI: 10.1053/j.gastro.2019.08.033] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
270 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
271 Paulides E, Pasma A, Erler NS, van Eijk RLA, de Vries AC, van der Woude CJ. Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 34181168 DOI: 10.1007/s10620-021-07118-8] [Reference Citation Analysis]
272 Li H, Lyu W. Intestinal NK/T cell lymphoma: A case report. World J Gastroenterol 2020; 26(27): 3989-3997 [PMID: 32774072 DOI: 10.3748/wjg.v26.i27.3989] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
273 Xue X, Bredell BX, Anderson ER, Martin A, Mays C, Nagao-Kitamoto H, Huang S, Győrffy B, Greenson JK, Hardiman K, Spence JR, Kamada N, Shah YM. Quantitative proteomics identifies STEAP4 as a critical regulator of mitochondrial dysfunction linking inflammation and colon cancer. Proc Natl Acad Sci U S A 2017;114:E9608-17. [PMID: 29078383 DOI: 10.1073/pnas.1712946114] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
274 Grażyńska A, Kufel J, Dudek A, Cebula M. Shear Wave and Strain Elastography in Crohn's Disease-A Systematic Review. Diagnostics (Basel) 2021;11:1609. [PMID: 34573952 DOI: 10.3390/diagnostics11091609] [Reference Citation Analysis]
275 Freeman K, Willis BH, Fraser H, Taylor-Phillips S, Clarke A. Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy. BMJ Open. 2019;9:e027428. [PMID: 30852550 DOI: 10.1136/bmjopen-2018-027428] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
276 Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther 2019;49:873-9. [PMID: 30773667 DOI: 10.1111/apt.15177] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
277 Allocca M, Craviotto V, Dell'Avalle C, Furfaro F, Zilli A, D'Amico F, Bonovas S, Peyrin-Biroulet L, Fiorino G, Danese S. Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease. Aliment Pharmacol Ther 2021. [PMID: 34783066 DOI: 10.1111/apt.16700] [Reference Citation Analysis]
278 Choukour M, Kivits J, Baker A, Baumann C, Guillemin F, Peyrin-Biroulet L. Personalised medicine in inflammatory bowel diseases: a patient survey. Scand J Gastroenterol 2019;54:135. [PMID: 30663451 DOI: 10.1080/00365521.2018.1555280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
279 Castro-Dopico T, Colombel JF, Mehandru S. Targeting B cells for inflammatory bowel disease treatment: back to the future. Curr Opin Pharmacol 2020;55:90-8. [PMID: 33166872 DOI: 10.1016/j.coph.2020.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
280 Tian M, Li D, Ma C, Feng Y, Hu X, Chen F. Barley Leaf Insoluble Dietary Fiber Alleviated Dextran Sulfate Sodium-Induced Mice Colitis by Modulating Gut Microbiota. Nutrients 2021;13:846. [PMID: 33807544 DOI: 10.3390/nu13030846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
281 Li N, Ouyang Y, Xu X, Yuan Z, Liu C, Zhu Z. MiR-155 promotes colitis-associated intestinal fibrosis by targeting HBP1/Wnt/β-catenin signalling pathway. J Cell Mol Med 2021;25:4765-75. [PMID: 33769664 DOI: 10.1111/jcmm.16445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
282 Ma Z, Zhen Y, Hu C, Yi H. Myeloid-Derived Suppressor Cell-Derived Arginase-1 Oppositely Modulates IL-17A and IL-17F Through the ESR/STAT3 Pathway During Colitis in Mice. Front Immunol 2020;11:687. [PMID: 32391010 DOI: 10.3389/fimmu.2020.00687] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
283 Freeman K, Ryan R, Parsons N, Taylor-Phillips S, Willis BH, Clarke A. Faecal calprotectin testing in UK general practice: a retrospective cohort study using The Health Improvement Network database. Br J Gen Pract 2021;71:e854-61. [PMID: 34607795 DOI: 10.3399/BJGP.2021.0125] [Reference Citation Analysis]
284 Brodersen JB, Andersen KW, Jensen MD. Adherence to the bowel cleansing regimen for pan-enteric capsule endoscopy in patients with suspected Crohn's disease and factors affecting the image quality. Scand J Gastroenterol 2021;:1-6. [PMID: 34915794 DOI: 10.1080/00365521.2021.2016945] [Reference Citation Analysis]
285 Amiot A, Seksik P, Reimund J, Nachury M, Altwegg R, Bourreille A, Viennot S, Fumery M, Roblin X, Serrero M, Allez M, Painchart C, Chanteloup E, Vuitton L, Fotsing G, Buisson A, Coulibaly B, Nancey S, Gilletta C, Plastaras L, Abitbol V, Guillo L, Simon M, Nahon S, Laharie D, Peyrin-biroulet L, Bouguen G, Amiot A, Gagniere C, Nachury M, Wils P, Bouhnik Y, Stefanescu C, Treton X, Martins C, Uzzan M, Serrero M, Guillo L, Roblin X, Tedesco ED, Beaugerie L, Seksik P, Bourrier A, Landmann C, Kirchgesner J, Sokol H, Buisson A, Nancey S, Boschetti G, Gay C, Danion P, Flourié B, Abitbol V, Malamut G, Reimund J, Caron B, Vuitton L, Peyrin-biroulet L, Zallot C, Gilletta C, Allez M, Gornet J, Baudry C, Viennot S, Bourreille A, Trang-poisson C, Boualit M, Painchart C, Plastaras L, Altwegg R, Boivineau L, Fumery M, Laharie D, Riviere P, Poullenot F, Coffin B, Duboc H, Nahon S, Simon M, Coulibaly B, Chanteloup E, Fotsing G. Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.04.011] [Reference Citation Analysis]
286 Bilski J, Mazur-Bialy A, Wojcik D, Surmiak M, Magierowski M, Sliwowski Z, Pajdo R, Kwiecien S, Danielak A, Ptak-Belowska A, Brzozowski T. Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases.Biomolecules. 2019;9. [PMID: 31779136 DOI: 10.3390/biom9120780] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
287 Panés J, D'Haens GR, Higgins PDR, Mele L, Moscariello M, Chan G, Wang W, Niezychowski W, Su C, Maller E. Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study. Aliment Pharmacol Ther 2019;49:265-76. [PMID: 30663107 DOI: 10.1111/apt.15072] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
288 Inoue A, Bartlett DJ, Shahraki N, Sheedy SP, Heiken JP, Voss BA, Fidler JL, Tootooni MS, Sir MY, Pasupathy K, Baker ME, Rieder F, Lightner AL, Deepak P, Bruining DH, Fletcher JG. Predicting Risk of Surgery in Patients With Small Bowel Crohn's Disease Strictures Using Computed Tomography and Magnetic Resonance Enterography. Inflamm Bowel Dis 2022:izab332. [PMID: 35032168 DOI: 10.1093/ibd/izab332] [Reference Citation Analysis]
289 Sun H, Huang X, Huo B, Tan Y, He T, Jiang X. Detecting sparse microbial association signals adaptively from longitudinal microbiome data based on generalized estimating equations. Brief Bioinform 2022:bbac149. [PMID: 35561307 DOI: 10.1093/bib/bbac149] [Reference Citation Analysis]
290 Caër C, Gorreja F, Forsskåhl SK, Brynjolfsson SF, Szeponik L, Magnusson MK, Börjesson LG, Block M, Bexe-Lindskog E, Wick MJ. TREM-1+ Macrophages Define a Pathogenic Cell Subset in the Intestine of Crohn's Disease Patients. J Crohns Colitis 2021;15:1346-61. [PMID: 33537747 DOI: 10.1093/ecco-jcc/jjab022] [Reference Citation Analysis]
291 Luo H, Cao G, Luo C, Tan D, Vong CT, Xu Y, Wang S, Lu H, Wang Y, Jing W. Emerging Pharmacotherapy for Inflammatory Bowel Diseases. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106146] [Reference Citation Analysis]
292 Nachury M, Bouhnik Y, Serrero M, Filippi J, Roblin X, Kirchgesner J, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWit O, Vuitton L, Matthieu N, Peyrin-Biroulet L, Gilletta C, Tadbiri S, Allez M, Viennot S, Bourreille A, Laharie D, Amiot A; GETAID-patient experience study group. Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. Dig Liver Dis 2021;53:434-41. [PMID: 33187920 DOI: 10.1016/j.dld.2020.10.020] [Reference Citation Analysis]
293 Wu Y, Shen J. Innate Lymphoid Cells in Crohn's Disease. Front Immunol 2020;11:554880. [PMID: 33329513 DOI: 10.3389/fimmu.2020.554880] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
294 Kim JE, Won H, Kim YH, Kim ER, Hong SN, Chang DK. Specificity of clinical decision support tools for vedolizumab and ustekinumab in biologically naïve patients with Crohn's disease. Scand J Gastroenterol 2021;:1-3. [PMID: 34967701 DOI: 10.1080/00365521.2021.2020332] [Reference Citation Analysis]
295 Wallden A, Graff P, Bryngelsson IL, Fornander L, Wiebert P, Vihlborg P. Risks of developing ulcerative colitis and Crohn's disease in relation to silica dust exposure in Sweden: a case-control study. BMJ Open 2020;10:e034752. [PMID: 32066610 DOI: 10.1136/bmjopen-2019-034752] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
296 Bravo F, Macpherson JA, Slack E, Patuto N, Cahenzli J, McCoy KD, Macpherson AJ, Juillerat P; SATICC (Sensitivity to Anti-TNF Inhibition in Crohn's disease and ulcerative Colitis) study group. Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up. Clin Transl Gastroenterol 2021;12:e00298. [PMID: 33735154 DOI: 10.14309/ctg.0000000000000298] [Reference Citation Analysis]
297 Tai J, Han MS, Kwak J, Kim TH. Association Between Microbiota and Nasal Mucosal Diseases in terms of Immunity. Int J Mol Sci 2021;22:4744. [PMID: 33947066 DOI: 10.3390/ijms22094744] [Reference Citation Analysis]
298 Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clin Gastroenterol Hepatol 2019;17:2497-2505.e1. [PMID: 30625408 DOI: 10.1016/j.cgh.2018.12.040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
299 Ali M, Ng S, Burgess P. Granulomatous Crohn's disease follows a more aggressive clinical course? Surg Pract 2021;25:78-81. [DOI: 10.1111/1744-1633.12488] [Reference Citation Analysis]
300 Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther 2020;51:831-42. [PMID: 32202328 DOI: 10.1111/apt.15685] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
301 Toyonaga T, Araba KC, Kennedy MM, Keith BP, Wolber EA, Beasley C, Steinbach EC, Schaner MR, Jain A, Long MD, Barnes EL, Herfarth HH, Isaacs KL, Hansen JJ, Kapadia M, Gaston Guillem J, Koruda MJ, Rahbar R, Sadiq T, Gulati AS, Sethupathy P, Furey TS, Ehre C, Sheikh SZ. Increased Colonic Expression of ACE2 Associates with Poor Prognosis in Crohn's disease. bioRxiv 2020:2020. [PMID: 33269348 DOI: 10.1101/2020.11.24.396382] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
302 Bangma A, Voskuil MD, Uniken Venema WTC, Brugge H, Hu S, Lanting P, Franke L, Dijkstra G, Festen EAM, Weersma RK. Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:1105-15. [PMID: 32363635 DOI: 10.1111/apt.15762] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
303 Rong JM, Luo J, Huang Q, Miao YL. Individualized selection of biological agents in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 893-900 [DOI: 10.11569/wcjd.v29.i15.893] [Reference Citation Analysis]
304 Curciarello R, Canziani KE, Salto I, Barbiera Romero E, Rocca A, Doldan I, Peton E, Brayer S, Sambuelli AM, Goncalves S, Tirado P, Correa GJ, Yantorno M, Garbi L, Docena GH, Serradell MLÁ, Muglia CI. Probiotic Lactobacilli Isolated from Kefir Promote Down-Regulation of Inflammatory Lamina Propria T Cells from Patients with Active IBD. Front Pharmacol 2021;12:658026. [PMID: 33935778 DOI: 10.3389/fphar.2021.658026] [Reference Citation Analysis]
305 Shaw AM, Qasem A, Naser SA. Modulation of PTPN2/22 Function by Spermidine in CRISPR-Cas9-Edited T-Cells Associated with Crohn's Disease and Rheumatoid Arthritis. Int J Mol Sci 2021;22:8883. [PMID: 34445589 DOI: 10.3390/ijms22168883] [Reference Citation Analysis]
306 Santos MPC, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease. Ann Gastroenterol. 2018;31:14-23. [PMID: 29333063 DOI: 10.20524/aog.2017.0208] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
307 Zhilu X, Xiangqian D, Keli Y, Caroline C, Jingwan Z, Yu L, Tao Z, Cheung CL, Yang S, Fengrui Z, Kl CF, Jy SJ, Jun Y, Anthony B, Nicolas B, Jean-Frédéric C, Sunny Hei W, Yinglei M, Siew C N. Association of Adherent-invasive Escherichia coli with severe Gut Mucosal dysbiosis in Hong Kong Chinese population with Crohn's disease. Gut Microbes 2021;13:1994833. [PMID: 34812117 DOI: 10.1080/19490976.2021.1994833] [Reference Citation Analysis]
308 D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, Olivera PA, Bossuyt P, Pouillon L, Louis E, Domènech E, Ghosh S, Danese S, Peyrin-Biroulet L. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J 2021;9:451-60. [PMID: 33961734 DOI: 10.1002/ueg2.12069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
309 Sinagra E, Raimondo D, Iacopinelli SM, Rossi F, Conoscenti G, Di Maggio MA, Testai S, Alloro R, Marasà M, Calandra A, Costanza C, Cristofalo S, Pallio S, Maida M, Tarantino I, Arena G. An Unusual Presentation of Crohn's Disease Diagnosed Following Accidental Ingestion of Fruit Pits: Report of Two Cases and Review of the Literature. Life (Basel) 2021;11:1415. [PMID: 34947946 DOI: 10.3390/life11121415] [Reference Citation Analysis]
310 Guillo L, D'Amico F, Serrero M, Angioi K, Loeuille D, Costanzo A, Danese S, Peyrin-Biroulet L. Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials. United European Gastroenterol J 2020;8:1013-30. [PMID: 32778004 DOI: 10.1177/2050640620950093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
311 Chen Y, Lei J, He S. m6A Modification Mediates Mucosal Immune Microenvironment and Therapeutic Response in Inflammatory Bowel Disease. Front Cell Dev Biol 2021;9:692160. [PMID: 34422815 DOI: 10.3389/fcell.2021.692160] [Reference Citation Analysis]
312 Zbroja M, Cyranka W, Kuczyńska M, Brodzisz A, Maria Woźniak M. Perianal lesions as an unusual first manifestation of Crohn's disease in pediatric patients - case series. J Ultrason 2020;20:e222-5. [PMID: 33365161 DOI: 10.15557/JoU.2020.0038] [Reference Citation Analysis]
313 Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol 2022;15:175628482210784. [DOI: 10.1177/17562848221078456] [Reference Citation Analysis]
314 Suárez-Fariñas M, Tokuyama M, Wei G, Huang R, Livanos A, Jha D, Levescot A, Irizar H, Kosoy R, Cording S, Wang W, Losic B, Ungaro RC, Di'Narzo A, Martinez-Delgado G, Suprun M, Corley MJ, Stojmirovic A, Houten SM, Peters L, Curran M, Brodmerkel C, Perrigoue J, Friedman JR, Hao K, Schadt EE, Zhu J, Ko HM, Cho J, Dubinsky MC, Sands BE, Ndhlovu L, Cerf-Bensusan N, Kasarskis A, Colombel JF, Harpaz N, Argmann C, Mehandru S. Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-related Disease. Gastroenterology 2021;160:287-301.e20. [PMID: 32980345 DOI: 10.1053/j.gastro.2020.09.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 10.5] [Reference Citation Analysis]
315 Hasbey I, Ufuk F, Kaya F, Celik M. Cardiac MRI findings in patients with Crohn's disease. Ir J Med Sci 2021. [PMID: 34279800 DOI: 10.1007/s11845-021-02717-w] [Reference Citation Analysis]
316 Venkatapurapu SP, Iwakiri R, Udagawa E, Patidar N, Qi Z, Takayama R, Kumar K, Sato Y, Behar M, Offner P, Dwivedi G, Miyasaka H, Suzuki RK, Hamada AL, D'Alessandro PM, Fernandez J. A Computational Platform Integrating a Mechanistic Model of Crohn's Disease for Predicting Temporal Progression of Mucosal Damage and Healing. Adv Ther 2022. [PMID: 35581423 DOI: 10.1007/s12325-022-02144-y] [Reference Citation Analysis]
317 Shin W, Hackley LA, Kim HJ. "Good Fences Make Good Neighbors": How does the Human Gut Microchip Unravel Mechanism of Intestinal Inflammation? Gut Microbes 2020;11:581-6. [PMID: 31198078 DOI: 10.1080/19490976.2019.1626684] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
318 Roszkowska A, Pawlicka M, Mroczek A, Bałabuszek K, Nieradko-Iwanicka B. Non-Celiac Gluten Sensitivity: A Review. Medicina (Kaunas) 2019;55:E222. [PMID: 31142014 DOI: 10.3390/medicina55060222] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
319 O'Connell L, Winter DC, Aherne CM. The Role of Organoids as a Novel Platform for Modeling of Inflammatory Bowel Disease. Front Pediatr 2021;9:624045. [PMID: 33681101 DOI: 10.3389/fped.2021.624045] [Reference Citation Analysis]
320 Rodríguez-Lago I, Hoyo JD, Pérez-Girbés A, Garrido-Marín A, Casanova MJ, Chaparro M, Fernández-Clotet A, Castro-Poceiro J, García MJ, Sánchez S, Ferreiro-Iglesias R, Bastón I, Piqueras M, Careda LEIB, Mena R, Suárez C, Cordón JP, López-García A, Márquez L, Arroyo M, Alfambra E, Sierra M, Cano N, Delgado-Guillena P, Morales-Alvarado V, Aparicio JC, Guerra I, Aulló C, Merino O, Arranz L, Hidalgo MA, Llaó J, Plaza R, Molina G, Torres P, Pérez-Galindo P, Romero MG, Herrera-deGuise C, Armesto E, Mesonero F, Frago-Larramona S, Benítez JM, Calvo M, Martín MDCL, Elorza A, Larena A, Peña E, Rodríguez-Grau MDC, Miguel-Criado J, Botella B, Olmos JA, López L, Aguirre U, Gisbert JP; Young GETECCU Group. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease. United European Gastroenterol J 2020;8:1056-66. [PMID: 32723069 DOI: 10.1177/2050640620947579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
321 Trilleaud C, Gauttier V, Biteau K, Girault I, Belarif L, Mary C, Pengam S, Teppaz G, Thepenier V, Danger R, Robert-Siegwald G, Néel M, Bruneau S, Glémain A, Néel A, Poupon A, Mosnier JF, Chêne G, Dubourdeau M, Blancho G, Vanhove B, Poirier N. Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution. Sci Adv 2021;7:eabd1453. [PMID: 33811066 DOI: 10.1126/sciadv.abd1453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
322 Tsai R, Mintz A, Lin M, Mhlanga J, Chiplunker A, Salter A, Ciorba M, Deepak P, Fowler K. Magnetic resonance enterography features of small bowel Crohn's disease activity: an inter-rater reliability study of small bowel active inflammation in clinical practice setting. Br J Radiol 2019;92:20180930. [PMID: 31141389 DOI: 10.1259/bjr.20180930] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
323 Sung J. Inflammatory bowel disease: Is East really differ from West? J Gastroenterol Hepatol 2020;35:357-8. [PMID: 32162386 DOI: 10.1111/jgh.15003] [Reference Citation Analysis]
324 Zhang Z, He X, Hu J, Zheng Z, Chen Y, Tang J, Li S, Ke J, Lian L, Lan P, Wu X. Split stoma with delayed anastomosis may be preferred for 2-stage surgical resection in high-risk patients with Crohn's disease. Surgery 2021:S0039-6060(21)01046-1. [PMID: 34863524 DOI: 10.1016/j.surg.2021.10.044] [Reference Citation Analysis]
325 Belarif L, Danger R, Kermarrec L, Nerrière-Daguin V, Pengam S, Durand T, Mary C, Kerdreux E, Gauttier V, Kucik A, Thepenier V, Martin JC, Chang C, Rahman A, Guen NS, Braudeau C, Abidi A, David G, Malard F, Takoudju C, Martinet B, Gérard N, Neveu I, Neunlist M, Coron E, MacDonald TT, Desreumaux P, Mai HL, Le Bas-Bernardet S, Mosnier JF, Merad M, Josien R, Brouard S, Soulillou JP, Blancho G, Bourreille A, Naveilhan P, Vanhove B, Poirier N. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Invest 2019;129:1910-25. [PMID: 30939120 DOI: 10.1172/JCI121668] [Cited by in Crossref: 33] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
326 Blesl A, Binder L, Högenauer C, Wenzl H, Borenich A, Pregartner G, Berghold A, Mestel S, Kump P, Baumann-Durchschein F, Petritsch W. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther 2021;54:667-77. [PMID: 34151449 DOI: 10.1111/apt.16478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
327 Malesza IJ, Malesza M, Krela-Kaźmierczak I, Zielińska A, Souto EB, Dobrowolska A, Eder P. Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. Int J Mol Sci 2020;21:E5223. [PMID: 32718006 DOI: 10.3390/ijms21155223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
328 Toyonaga T, Araba KC, Kennedy MM, Keith BP, Wolber EA, Beasley C, Steinbach EC, Schaner MR, Jain A, Long MD, Barnes EL, Herfarth HH, Isaacs KL, Hansen JJ, Kapadia MR, Guillem JG, Gulati AS, Sethupathy P, Furey TS, Ehre C, Sheikh SZ. Increased colonic expression of ACE2 associates with poor prognosis in Crohn's disease. Sci Rep 2021;11:13533. [PMID: 34188154 DOI: 10.1038/s41598-021-92979-2] [Reference Citation Analysis]
329 Nardone OM, Rispo A, Testa A, Imperatore N, Pellegrini L, Guarino AD, Ricciolino S, Patturelli M, De Palma G, Castiglione F. The impact of a dedicated contact centre on the clinical outcome of patients with inflammatory bowel disease during the COVID-19 outbreak. Therap Adv Gastroenterol 2020;13:1756284820959586. [PMID: 33024453 DOI: 10.1177/1756284820959586] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
330 Rasmussen NF, Bech BH, Rubin KH, Andersen V. Associations between participation in, intensity of, and time spent on leisure time physical activity and risk of inflammatory bowel disease among older adults (PA-IBD): a prospective cohort study. BMC Public Health 2021;21:634. [PMID: 33794834 DOI: 10.1186/s12889-021-10492-7] [Reference Citation Analysis]
331 Louis E. Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease. Front Med (Lausanne) 2019;6:302. [PMID: 31970158 DOI: 10.3389/fmed.2019.00302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
332 Voskuil MD, Spekhorst LM, van der Sloot KWJ, Jansen BH, Dijkstra G, van der Woude CJ, Hoentjen F, Pierik MJ, van der Meulen AE, de Boer NKH, Löwenberg M, Oldenburg B, Festen EAM, Weersma RK. Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes. J Crohns Colitis 2021;15:930-7. [PMID: 33152062 DOI: 10.1093/ecco-jcc/jjaa223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
333 Dhaliwal A, Quinlan JI, Overthrow K, Greig C, Lord JM, Armstrong MJ, Cooper SC. Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview. Nutrients 2021;13:656. [PMID: 33671473 DOI: 10.3390/nu13020656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
334 Kamath C, Brenner EJ. The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic. Curr Res Pharmacol Drug Discov 2022;3:100101. [PMID: 35496814 DOI: 10.1016/j.crphar.2022.100101] [Reference Citation Analysis]
335 Wan Q, Zhao R, Xia L, Wu Y, Zhou Y, Wang Y, Cui Y, Shen X, Wu XT. Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: a meta-analysis of 26 observational studies. J Cancer Res Clin Oncol 2021;147:1077-87. [PMID: 33433655 DOI: 10.1007/s00432-020-03496-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
336 Preidis GA, Weizman AV, Kashyap PC, Morgan RL. AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology 2020;159:708-738.e4. [PMID: 32531292 DOI: 10.1053/j.gastro.2020.05.060] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
337 Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
338 Aljabban J, Rohr M, Borkowski VJ, Nemer M, Cohen E, Hashi N, Aljabban H, Boateng E, Syed S, Mohammed M, Mukhtar A, Hadley D, Panahiazar M. Probing predilection to Crohn's disease and Crohn's disease flares: A crowd-sourced bioinformatics approach. Journal of Pathology Informatics 2022. [DOI: 10.1016/j.jpi.2022.100094] [Reference Citation Analysis]
339 Shimizu Y, Nakamura K, Yoshii A, Yokoi Y, Kikuchi M, Shinozaki R, Nakamura S, Ohira S, Sugimoto R, Ayabe T. Paneth cell α-defensin misfolding correlates with dysbiosis and ileitis in Crohn's disease model mice. Life Sci Alliance 2020;3:e201900592. [PMID: 32345659 DOI: 10.26508/lsa.201900592] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
340 Collij V, Klaassen MAY, Weersma RK, Vila AV. Gut microbiota in inflammatory bowel diseases: moving from basic science to clinical applications. Hum Genet 2021;140:703-8. [PMID: 32857194 DOI: 10.1007/s00439-020-02218-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Bettenworth D, Bokemeyer A, Kou L, Lopez R, Bena JF, El Ouali S, Mao R, Kurada S, Bhatt A, Beyna T, Halloran B, Reeson M, Hosomi S, Kishi M, Hirai F, Ohmiya N, Rieder F. Systematic review with meta-analysis: efficacy of balloon-assisted enteroscopy for dilation of small bowel Crohn's disease strictures.Aliment Pharmacol Ther. 2020;52:1104-1116. [PMID: 32813282 DOI: 10.1111/apt.16049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
342 Yu B, Zhao L, Jin S, He H, Zhang J, Wang X. Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn’s Disease. Front Immunol 2022;13:828219. [DOI: 10.3389/fimmu.2022.828219] [Reference Citation Analysis]
343 Wan J, Liu C, Yuan XQ, Yang MQ, Wu XC, Gao RY, Yin L, Chen CQ. Laparoscopy for Crohn's disease: A comprehensive exploration of minimally invasive surgical techniques. World J Gastrointest Surg 2021; 13(10): 1190-1201 [PMID: 34754387 DOI: 10.4240/wjgs.v13.i10.1190] [Reference Citation Analysis]
344 Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48:65-77. [PMID: 29797519 DOI: 10.1111/apt.14794] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 16.5] [Reference Citation Analysis]
345 Juliao-baños F, Puentes F, López R, Saffon M, Reyes G, Parra V, Galiano M, Barraza M, Molano J, Álvarez E, Corrales R, Vargas L, Gil F, Álvarez P, Limas L, Prieto R, Yance P, Díaz F, Bareño J, Juliao-baños F, Arrubla M, Camargo J, Puentes F, Arango L, López R, García R, Mendoza B, Saffon MA, Roldan LF, Zuleta J, Reyes G, Parra V, Flórez C, Nuñez E, Galiano MT, Barraza M, Sanchez IC, Molano JL, Lizarazo JI, Cuellar I, Álvarez E, Corrales R, Gil F, Vargas LE, Álvarez P, Limas LM, Prieto R, Ballén H, Delgado L, Yance P, Díaz F. Characterization of inflammatory bowel disease in Colombia: Results of a national register. Revista de Gastroenterología de México (English Edition) 2021;86:153-62. [DOI: 10.1016/j.rgmxen.2020.05.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Marra M, Cioffi I, Morlino D, Vincenzo OD, Pagano MC, Imperatore N, Alfonsi L, Santarpia L, Castiglione F, Scalfi L, Pasanisi F. New Predictive Equations for Estimating Resting Energy Expenditure in Adults With Crohn's Disease. JPEN J Parenter Enteral Nutr 2020;44:1021-8. [PMID: 32010994 DOI: 10.1002/jpen.1790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
347 Cioffi I, Imperatore N, Di Vincenzo O, Santarpia L, Rispo A, Marra M, Testa A, Contaldo F, Castiglione F, Pasanisi F. Association between Health-Related Quality of Life and Nutritional Status in Adult Patients with Crohn's Disease. Nutrients 2020;12:E746. [PMID: 32168964 DOI: 10.3390/nu12030746] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
348 Hou Q, Huang J, Ayansola H, Masatoshi H, Zhang B. Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases. Front Immunol 2020;11:623691. [PMID: 33584726 DOI: 10.3389/fimmu.2020.623691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
349 Palmese F, Del Toro R, Di Marzio G, Cataleta P, Sama MG, Domenicali M. Sarcopenia and Vitamin D Deficiency in Patients with Crohn's Disease: Pathological Conditions That Should Be Linked Together. Nutrients 2021;13:1378. [PMID: 33923948 DOI: 10.3390/nu13041378] [Reference Citation Analysis]
350 Colombel JF, D'haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2020;14:254-266. [PMID: 31403666 DOI: 10.1093/ecco-jcc/jjz131] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 25.0] [Reference Citation Analysis]
351 Loktionov A. Eosinophils in the gastrointestinal tract and their role in the pathogenesis of major colorectal disorders. World J Gastroenterol 2019; 25(27): 3503-3526 [PMID: 31367153 DOI: 10.3748/wjg.v25.i27.3503] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
352 Di Narzo A, Frades I, Crane HM, Crane PK, Hulot JS, Kasarskis A, Hart A, Argmann C, Dubinsky M, Peter I, Hao K. Meta-analysis of sample-level dbGaP data reveals novel shared genetic link between body height and Crohn's disease. Hum Genet 2021;140:865-77. [PMID: 33452914 DOI: 10.1007/s00439-020-02250-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
353 Bezzio C, Vernero M, Ribaldone DG, Manes G, Saibeni S. Insights into the role of gastrointestinal ultrasound in ulcerative colitis. Therap Adv Gastroenterol 2021;14:17562848211051456. [PMID: 34707688 DOI: 10.1177/17562848211051456] [Reference Citation Analysis]
354 Axelrad JE, Sachs MC, Ludvigsson JF, Olén O; SWIBREG Study Group. A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data. Clin Epidemiol 2020;12:1059-72. [PMID: 33116900 DOI: 10.2147/CLEP.S265404] [Reference Citation Analysis]
355 Dell'Avalle C, D'Amico F, Gabbiadini R, Dal Buono A, Pugliese N, Zilli A, Furfaro F, Fiorino G, Allocca M, Peyrin-Biroulet L, Danese S. JAK inhibitors in crohn's disease: ready to go? Expert Opin Investig Drugs 2022;31:145-61. [PMID: 35164629 DOI: 10.1080/13543784.2022.2032639] [Reference Citation Analysis]
356 Sarto J, Caballol B, Berenguer J, Aldecoa I, Carbayo Á, Santana D, Archilla I, Gaig C, Graus F, Panés J, Saiz A. Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature. Ther Adv Neurol Disord 2022;15:175628642210796. [DOI: 10.1177/17562864221079682] [Reference Citation Analysis]
357 AlRuthia Y, Alharbi O, Aljebreen AM, Azzam NA, Almadi MA, Bahari OH, Almalki KA, Atham AT, Alanazi AS, Saeed M, HajkhderMullaissa B, Alsenaidy M, Balkhi B. Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia. Cost Eff Resour Alloc 2019;17:25. [PMID: 31827409 DOI: 10.1186/s12962-019-0194-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
358 Laganà B, Zullo A, Scribano ML, Chimenti MS, Migliore A, Picchianti Diamanti A, Lorenzetti R, Scolieri P, Ridola L, Ortona E, Pierdominici M, Bruzzese V. Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. Front Pharmacol 2019;10:47. [PMID: 30745872 DOI: 10.3389/fphar.2019.00047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
359 Jefremow A, Neurath MF. All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective. Immunotargets Ther 2020;9:289-97. [PMID: 33274187 DOI: 10.2147/ITT.S282466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
360 Zhang J, Wang XJ, Wu LJ, Yang L, Yang YT, Zhang D, Hong J, Li XY, Dong XQ, Guo XC, Han R, Ma X. Herb-partitioned moxibustion alleviates colonic inflammation in Crohn's disease rats by inhibiting hyperactivation of the NLRP3 inflammasome via regulation of the P2X7R-Pannexin-1 signaling pathway. PLoS One 2021;16:e0252334. [PMID: 34043726 DOI: 10.1371/journal.pone.0252334] [Reference Citation Analysis]
361 Ruiz MA, Junior RLK, Piron-Ruiz L, Saran PS, Castiglioni L, Quadros LG, Pinho TS, Burt RK. Medical, ethical, and legal aspects of hematopoietic stem cell transplantation for Crohn’s disease in Brazil. World J Stem Cells 2020; 12(10): 1113-1123 [PMID: 33178395 DOI: 10.4252/wjsc.v12.i10.1113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
362 Shen Y, Shi L, Zhang J, Zhu H, Yao Y, Liu Z, Zou X, Zhang X. Thromboelastography in Patients with Inflammatory Bowel Disease. Gastroenterol Res Pract 2020;2020:3245657. [PMID: 32565780 DOI: 10.1155/2020/3245657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
363 Caviglia GP, Rosso C, Stalla F, Rizzo M, Massano A, Abate ML, Olivero A, Armandi A, Vanni E, Younes R, Fagoonee S, Pellicano R, Astegiano M, Saracco GM, Bugianesi E, Ribaldone DG. On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. J Clin Med 2020;9:E800. [PMID: 32183476 DOI: 10.3390/jcm9030800] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
364 Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hébuterne X, Ferrante M, Rogler G, Fumery M, Danese S, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollón F, Gubonina I, Schreiber S, Motoya S, Hellström PM, Halfvarson J, Butler JW, Petersson J, Petralia F, Colombel JF. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology 2020;159:139-47. [PMID: 32224129 DOI: 10.1053/j.gastro.2020.03.039] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 14.5] [Reference Citation Analysis]
365 Cui Z, Hou G, Meng X, Feng H, He B, Tian Y. Bidirectional Causal Associations Between Inflammatory Bowel Disease and Ankylosing Spondylitis: A Two-Sample Mendelian Randomization Analysis. Front Genet 2020;11:587876. [PMID: 33329731 DOI: 10.3389/fgene.2020.587876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
366 Scribano ML, Aratari A, Neri B, Bezzio C, Balestrieri P, Baccolini V, Falasco G, Camastra C, Pantanella P, Monterubbianesi R, Tullio A, Saibeni S, Papi C, Biancone L, Cosintino R, Faggiani R. Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy. Therap Adv Gastroenterol 2022;15:175628482110724. [DOI: 10.1177/17562848211072412] [Reference Citation Analysis]
367 Sperger J, Shah KS, Lu M, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD, Kosorok MR. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open 2021;11:e049740. [PMID: 34772750 DOI: 10.1136/bmjopen-2021-049740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
368 Martin JC, Chang C, Boschetti G, Ungaro R, Giri M, Grout JA, Gettler K, Chuang LS, Nayar S, Greenstein AJ, Dubinsky M, Walker L, Leader A, Fine JS, Whitehurst CE, Mbow ML, Kugathasan S, Denson LA, Hyams JS, Friedman JR, Desai PT, Ko HM, Laface I, Akturk G, Schadt EE, Salmon H, Gnjatic S, Rahman AH, Merad M, Cho JH, Kenigsberg E. Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. Cell 2019;178:1493-1508.e20. [PMID: 31474370 DOI: 10.1016/j.cell.2019.08.008] [Cited by in Crossref: 157] [Cited by in F6Publishing: 147] [Article Influence: 52.3] [Reference Citation Analysis]
369 Li H, Mo Y, Huang C, Ren Q, Xia X, Nan X, Shuai X, Meng X. An MSCT-based radiomics nomogram combined with clinical factors can identify Crohn's disease and ulcerative colitis. Ann Transl Med 2021;9:572. [PMID: 33987270 DOI: 10.21037/atm-21-1023] [Reference Citation Analysis]
370 Rajbhandari R, Blakemore S, Gupta N, Adler AJ, Noble CA, Mannan S, Nikolli K, Yih A, Joshi S, Bukhman G. Crohn’s disease in low and lower-middle income countries: A scoping review. World J Gastroenterol 2020; 26(43): 6891-6908 [PMID: 33268969 DOI: 10.3748/wjg.v26.i43.6891] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
371 Axelrad JE, Cadwell KH, Colombel JF, Shah SC. Systematic review: gastrointestinal infection and incident inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:1222-32. [PMID: 32372471 DOI: 10.1111/apt.15770] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
372 Vadstrup K, Bendtsen F. Anti-NKG2D mAb: A New Treatment for Crohn's Disease? Int J Mol Sci 2017;18:E1997. [PMID: 28926962 DOI: 10.3390/ijms18091997] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
373 Levin A, Risto A, Myrelid P. The changing landscape of surgery for Crohn's disease. Seminars in Colon and Rectal Surgery 2020;31:100740. [DOI: 10.1016/j.scrs.2020.100740] [Reference Citation Analysis]
374 Fleming A, Castro-Dopico T, Clatworthy MR. B cell class switching in intestinal immunity in health and disease. Scand J Immunol 2022;95:e13139. [PMID: 34978077 DOI: 10.1111/sji.13139] [Reference Citation Analysis]
375 Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021;70:725-32. [PMID: 33082265 DOI: 10.1136/gutjnl-2020-322539] [Cited by in Crossref: 59] [Cited by in F6Publishing: 76] [Article Influence: 29.5] [Reference Citation Analysis]
376 Martins KR, Araújo JM, Cruz ÁC, Luiz-Ferreira A. EPIDEMIOLOGIC ASPECTS OF INFLAMMATORY BOWEL DISEASE IN THE WESTERN REGION OF MINAS GERAIS STATE. Arq Gastroenterol 2021;58:377-83. [PMID: 34705974 DOI: 10.1590/S0004-2803.202100000-63] [Reference Citation Analysis]
377 Keewan E, Narasimhulu CA, Rohr M, Hamid S, Parthasarathy S. Are Fried Foods Unhealthy? The Dietary Peroxidized Fatty Acid, 13-HPODE, Induces Intestinal Inflammation In Vitro and In Vivo. Antioxidants (Basel) 2020;9:E926. [PMID: 32992618 DOI: 10.3390/antiox9100926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
378 Paulides E, Cornelissen D, de Vries AC, van der Woude CJ. Inflammatory bowel disease negatively impacts household and family life. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-102027] [Reference Citation Analysis]
379 Le Berre C, Loy L, Lönnfors S, Avedano L, Piovani D. Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations. World J Gastroenterol 2020; 26(29): 4343-4355 [PMID: 32848338 DOI: 10.3748/wjg.v26.i29.4343] [Reference Citation Analysis]
380 Ferreiro B, Llopis-Salinero S, Lardies B, Granados-Colomina C, Milà-Villarroel R. Clinical and Nutritional Impact of a Semi-Elemental Hydrolyzed Whey Protein Diet in Patients with Active Crohn's Disease: A Prospective Observational Study. Nutrients 2021;13:3623. [PMID: 34684624 DOI: 10.3390/nu13103623] [Reference Citation Analysis]
381 Linares R, Gutiérrez A, Márquez-galera Á, Caparrós E, Aparicio JR, Madero L, Payá A, López-atalaya JP, Francés R. Transcriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn’s disease. Biomedicine & Pharmacotherapy 2022;147:112653. [DOI: 10.1016/j.biopha.2022.112653] [Reference Citation Analysis]
382 Marafini I, Salvatori S, Troncone E, Scarozza P, Fantini E, Monteleone G. No effect of a liquid diet in the management of patients with stricturing Crohn's disease. Int J Colorectal Dis 2020;35:1881-5. [PMID: 32504336 DOI: 10.1007/s00384-020-03650-7] [Reference Citation Analysis]
383 Kornelsen J, Wilson A, Labus JS, Witges K, Mayer EA, Bernstein CN. Brain Resting-State Network Alterations Associated With Crohn's Disease. Front Neurol 2020;11:48. [PMID: 32132964 DOI: 10.3389/fneur.2020.00048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
384 D'Amico F, Peyrin-Biroulet L, Danese S. Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm. J Crohns Colitis 2022;16:ii30-41. [PMID: 35553665 DOI: 10.1093/ecco-jcc/jjac011] [Reference Citation Analysis]
385 Rennie S, Dalby M, van Duin L, Andersson R. Transcriptional decomposition reveals active chromatin architectures and cell specific regulatory interactions. Nat Commun 2018;9:487. [PMID: 29402885 DOI: 10.1038/s41467-017-02798-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
386 Alyaseer AAA, de Lima MHS, Braga TT. The Role of NLRP3 Inflammasome Activation in the Epithelial to Mesenchymal Transition Process During the Fibrosis. Front Immunol 2020;11:883. [PMID: 32508821 DOI: 10.3389/fimmu.2020.00883] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
387 Casas Deza D, Llorente Barrio M, Monzón Baez RM, Lamuela Calvo LJ, Gascón Ruiz M, Ramos Lisbona AI, García López S. It is not always Crohn's disease: Amebiasis as a differential diagnosis of inflammatory bowel disease. Gastroenterol Hepatol 2019;42:548-9. [PMID: 31122655 DOI: 10.1016/j.gastrohep.2019.03.006] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
388 Gutiérrez A, Rodríguez-Lago I. How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Front Med (Lausanne) 2021;8:640813. [PMID: 33585530 DOI: 10.3389/fmed.2021.640813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
389 Marafini I, Di Fusco D, Dinallo V, Franzè E, Stolfi C, Sica G, Monteleone G, Monteleone I. NPD-0414-2 and NPD-0414-24, Two Chemical Entities Designed as Aryl Hydrocarbon Receptor (AhR) Ligands, Inhibit Gut Inflammatory Signals. Front Pharmacol 2019;10:380. [PMID: 31031628 DOI: 10.3389/fphar.2019.00380] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
390 Ward MC, Studer B, Nora I, Seepaulsing N, Loewe C. Primary Sclerosing Cholangitis in Crohn's Disease: An Atypical Complication. Cureus 2021;13:e14964. [PMID: 34123661 DOI: 10.7759/cureus.14964] [Reference Citation Analysis]
391 Kim HM, Kim JW, Kim HS, Kim JS, Kim YS, Cheon JH, Kim WH, Ye BD, Moon W, Jung SH, Kim YH, Han DS. Effect of Thiopurine on Potential Surgical Intervention in Crohn’s Disease in Korea: Results from the CONNECT Study. J Clin Med 2020;10:E25. [PMID: 33374886 DOI: 10.3390/jcm10010025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
392 Zakharevich NV, Nikitin MS, Kovtun AS, Malov VO, Averina OV, Danilenko VN, Artamonova II. CRISPR-Cas Systems in Gut Microbiome of Children with Autism Spectrum Disorders. Life 2022;12:367. [DOI: 10.3390/life12030367] [Reference Citation Analysis]
393 Kim ES, Choi S, Choi SY, Park JH, Choe BH, Lee SY, Kim MJ, Choe YH, Kang B. NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine. Aliment Pharmacol Ther 2022. [PMID: 35032047 DOI: 10.1111/apt.16769] [Reference Citation Analysis]
394 Kamel S, Sakr M, Hamed W, Eltabbakh M, Sherief A, Rashad H, Elghamrini Y, Elbaz A. Characterization of Crohn's disease patients in Egypt: Risk factors for postoperative recurrence (A cohort study). Ann Med Surg (Lond) 2021;69:102781. [PMID: 34527234 DOI: 10.1016/j.amsu.2021.102781] [Reference Citation Analysis]
395 Yau YY, Wasinger VC, Hirten RP, Chuang E, Huntsman M, Stylli J, Shimizu J, Yajnik V, Smith J, Lee SN, Singh S, Wahl C, Leong RW, Sands BE. Current Trends in IBD-Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System. Inflamm Bowel Dis 2021;27:S17-24. [PMID: 34791290 DOI: 10.1093/ibd/izab179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
396 Jiang C, Zhu P, Shi Y, Xiang W, Ge S, Zhang Z, Zuo L. [Protective effect of procyanidin B2 on intestinal barrier and against enteritis in a mouse model of trinitrobenzene sulphonic acid-induced colitis]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:778-83. [PMID: 31340909 DOI: 10.12122/j.issn.1673-4254.2019.07.05] [Reference Citation Analysis]
397 Masu Y, Kanazawa Y, Kakuta Y, Shimoyama Y, Onodera M, Naito T, Moroi R, Kuroha M, Kimura T, Shiga H, Kinouchi Y, Masamune A. Immunoglobulin subtype-coated bacteria are correlated with the disease activity of inflammatory bowel disease. Sci Rep 2021;11:16672. [PMID: 34404881 DOI: 10.1038/s41598-021-96289-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
398 Al Sulais E, AlAmeel T. Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease. Biologics 2020;14:1-11. [PMID: 32021084 DOI: 10.2147/BTT.S236433] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
399 Fauny M, Moulin D, D'Amico F, Netter P, Petitpain N, Arnone D, Jouzeau JY, Loeuille D, Peyrin-Biroulet L. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis 2020;79:1132-8. [PMID: 32719044 DOI: 10.1136/annrheumdis-2020-217927] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
400 Zeze K, Hirano A, Torisu T, Esaki M, Moriyama T, Umeno J, Kawasaki K, Fujioka S, Fuyuno Y, Matsuno Y, Kitazono T. Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn's Disease: A Retrospective Study. Dig Dis Sci 2021;66:3124-31. [PMID: 32920717 DOI: 10.1007/s10620-020-06600-z] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
401 He Q, Gao Y, Jie Z, Yu X, Laursen JM, Xiao L, Li Y, Li L, Zhang F, Feng Q, Li X, Yu J, Liu C, Lan P, Yan T, Liu X, Xu X, Yang H, Wang J, Madsen L, Brix S, Wang J, Kristiansen K, Jia H. Two distinct metacommunities characterize the gut microbiota in Crohn's disease patients. Gigascience. 2017;6:1-11. [PMID: 28655159 DOI: 10.1093/gigascience/gix050] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
402 He Q. Cardiocerebral and peripheral vascular risks in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2019; 27(5): 341-346 [DOI: 10.11569/wcjd.v27.i5.341] [Reference Citation Analysis]
403 Singh K, Gobert AP, Coburn LA, Barry DP, Allaman M, Asim M, Luis PB, Schneider C, Milne GL, Boone HH, Shilts MH, Washington MK, Das SR, Piazuelo MB, Wilson KT. Dietary Arginine Regulates Severity of Experimental Colitis and Affects the Colonic Microbiome. Front Cell Infect Microbiol 2019;9:66. [PMID: 30972302 DOI: 10.3389/fcimb.2019.00066] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
404 Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF. Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies. J Crohns Colitis 2019;13:725-34. [PMID: 30753371 DOI: 10.1093/ecco-jcc/jjy223] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
405 Mertelj T, Smrekar N, Kojc N, Lindič J, Kovač D. IgA Nephropathy in a Patient Treated with Adalimumab. Case Rep Nephrol Dial 2021;11:233-40. [PMID: 34595210 DOI: 10.1159/000515585] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
406 Sun D, Ge X, Tang S, Liu Y, Sun J, Zhou Y, Luo L, Xu Z, Zhou W, Sheng J. Bacterial Characteristics of Intestinal Tissues From Patients With Crohn's Disease. Front Cell Infect Microbiol 2021;11:711680. [PMID: 34869050 DOI: 10.3389/fcimb.2021.711680] [Reference Citation Analysis]
407 Majtner T, Brodersen JB, Herp J, Kjeldsen J, Halling ML, Jensen MD. A deep learning framework for autonomous detection and classification of Crohn's disease lesions in the small bowel and colon with capsule endoscopy. Endosc Int Open 2021;9:E1361-70. [PMID: 34466360 DOI: 10.1055/a-1507-4980] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
408 Lai Y, Xue J, Liu CW, Gao B, Chi L, Tu P, Lu K, Ru H. Serum Metabolomics Identifies Altered Bioenergetics, Signaling Cascades in Parallel with Exposome Markers in Crohn's Disease. Molecules 2019;24:E449. [PMID: 30691236 DOI: 10.3390/molecules24030449] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
409 Hao X, Feng T, Yang Y, Shi Y, Jing R, Liu S, Luo Y, Qiao Y, Zhong M, Yu M. Laparoscopic bowel resection combined with infliximab treatment (LaRIC) versus infliximab for terminal ileitis in Crohn's disease: a randomised, controlled, open-label trial. BMJ Open 2020;10:e038429. [PMID: 33199421 DOI: 10.1136/bmjopen-2020-038429] [Reference Citation Analysis]
410 Fiorillo C, Schena CA, Quero G, Laterza V, Pugliese D, Privitera G, Rosa F, Schepis T, Salvatore L, Di Stefano B, Larosa L, Minordi LM, Natale L, Tortora G, Armuzzi A, Alfieri S. Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis. Cancers (Basel) 2021;13:574. [PMID: 33540674 DOI: 10.3390/cancers13030574] [Reference Citation Analysis]
411 Bustamante P, Vidal R. Repertoire and Diversity of Toxin - Antitoxin Systems of Crohn's Disease-Associated Adherent-Invasive Escherichia coli. New Insight of T his Emergent E. coli Pathotype. Front Microbiol 2020;11:807. [PMID: 32477289 DOI: 10.3389/fmicb.2020.00807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
412 Barnes EL, Hudson J, Esckilsen S, Kochar B, Kappelman MD, Long MD, Koruda M, Sandler RS, Herfarth HH. Transmural Inflammation, Ileitis, and Granulomas at the Time of Proctocolectomy in Patients with Ulcerative Colitis Do Not Predict Future Development of Pouchitis. Inflamm Intest Dis 2021;6:210-7. [PMID: 35083286 DOI: 10.1159/000519325] [Reference Citation Analysis]
413 Haider SA, Yadav A, Perry C, Su L, Akanbi O, Kudaravalli P, Tripathi N, Hashim MA, Abdelsalam M, Hussein M, Elkheshen A, Patel V, Ali SE, Lamb L, Ingram K, Mayne C, Stuffelbeam AB, Flomenhoft D, Stromberg A, Barrett TA. Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820959245. [PMID: 33133239 DOI: 10.1177/1756284820959245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
414 Juliao-Baños F, Puentes F, López R, Saffon MA, Reyes G, Parra V, Galiano MT, Barraza M, Molano J, Álvarez E, Corrales R, Vargas LE, Gil F, Álvarez P, Limas L, Prieto R, Yance P, Díaz F, Bareño J; Grupo del Registro Colombiano de Enfermedad Inflamatoria Intestinal., Grupo Registro Colombiano de Enfermedad Inflamatoria Intestinal. Characterization of inflammatory bowel disease in Colombia: Results of a national register. Rev Gastroenterol Mex (Engl Ed) 2021;86:153-62. [PMID: 32723624 DOI: 10.1016/j.rgmx.2020.05.005] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
415 Guillo L, Delanaye P, Flamant M, Figueres L, Karam S, Lemoine S, Benezech A, Pelletier AL, Amiot A, Caron B, Stefanescu C, Boschetti G, Bouguen G, Rahier JF, Gornet JM, Hugot JP, Bonnet J, Vuitton L, Nachury M, Vidon M, Uzzan M, Serrero M, Dib N, Seksik P, Hebuterne X, Bertocchio JP, Mariat C, Peyrin-Biroulet L. Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Dig Liver Dis 2021:S1590-8658(21)00848-3. [PMID: 34866011 DOI: 10.1016/j.dld.2021.11.008] [Reference Citation Analysis]
416 Ochi M, Niikura R, Otsubo T, Yamada A, Kawai T, Koike K. Comparison of inflammatory bowel disease relapse after top-down or step-up therapy: a population-based cohort study. Int J Colorectal Dis 2021;36:2227-35. [PMID: 34386841 DOI: 10.1007/s00384-021-04007-4] [Reference Citation Analysis]
417 Jordan DR, Park JSY, Al-Breiki D. Acute orbital inflammation with loss of vision: a paradoxical adverse event associated with infliximab therapy for Crohn's disease. Orbit 2021;:1-6. [PMID: 34120561 DOI: 10.1080/01676830.2021.1939726] [Reference Citation Analysis]
418 Ungaro RC, Limketkai BN, Jensen CB, Yzet C, Allin KH, Agrawal M, Ullman T, Burisch J, Jess T, Colombel JF. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. Clin Gastroenterol Hepatol 2020;18:1152-1160.e1. [PMID: 31419574 DOI: 10.1016/j.cgh.2019.08.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
419 de Campos-Lobato LF, Kiran RP. Surgical Management of Complex Enteric Fistulas in Crohn's Disease. Clin Colon Rectal Surg 2019;32:268-72. [PMID: 31275073 DOI: 10.1055/s-0039-1683909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
420 Zheng Y, Ge W, Ma Y, Xie G, Wang W, Han L, Bian B, Li L, Shen L. miR-155 Regulates IL-10-Producing CD24hiCD27+ B Cells and Impairs Their Function in Patients with Crohn's Disease. Front Immunol 2017;8:914. [PMID: 28824639 DOI: 10.3389/fimmu.2017.00914] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
421 Hadid B, Buehring W, Mannino A, Weisberg MD, Golub IJ, Ng MK, Razi AE. Crohn's Disease Increases In-Hospital Lengths of Stay, Medical Complications, and Costs of Care following Primary Total Knee Arthroplasty. J Knee Surg 2021. [PMID: 34794196 DOI: 10.1055/s-0041-1739199] [Reference Citation Analysis]
422 Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn's Disease. Int J Mol Sci 2018;19:E2244. [PMID: 30065229 DOI: 10.3390/ijms19082244] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 20.0] [Reference Citation Analysis]
423 Özkoç M, Can B, Şentürk H, Burukoğlu Dönmez D, Kanbak G. Possible Curative Effects of Boric Acid and Bacillus clausii Treatments on TNBS-Induced Ulcerative Colitis in Rats. Biol Trace Elem Res. [DOI: 10.1007/s12011-022-03215-5] [Reference Citation Analysis]
424 Caioni G, Viscido A, d'Angelo M, Panella G, Castelli V, Merola C, Frieri G, Latella G, Cimini A, Benedetti E. Inflammatory Bowel Disease: New Insights into the Interplay between Environmental Factors and PPARγ. Int J Mol Sci 2021;22:985. [PMID: 33498177 DOI: 10.3390/ijms22030985] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
425 Ungaro RC, Yarur A, Jossen J, Phan BL, Chefitz E, Sehgal P, Kamal K, Bruss A, Beniwal-Patel P, Fox C, Patel A, Bahur B, Jain A, Stein D, Naik S, Dubinsky MC. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease. J Crohns Colitis 2019;13:963-9. [PMID: 31087100 DOI: 10.1093/ecco-jcc/jjz041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
426 Suri K, Bubier JA, Wiles MV, Shultz LD, Amiji MM, Hosur V. Role of MicroRNA in Inflammatory Bowel Disease: Clinical Evidence and the Development of Preclinical Animal Models. Cells 2021;10:2204. [PMID: 34571853 DOI: 10.3390/cells10092204] [Reference Citation Analysis]
427 Linares R, Francés R, Gutiérrez A, Juanola O. Bacterial Translocation as Inflammatory Driver in Crohn's Disease. Front Cell Dev Biol 2021;9:703310. [PMID: 34557484 DOI: 10.3389/fcell.2021.703310] [Reference Citation Analysis]
428 Zhuang X, Liu C, Zhan S, Tian Z, Li N, Mao R, Zeng Z, Chen M. Gut Microbiota Profile in Pediatric Patients With Inflammatory Bowel Disease: A Systematic Review. Front Pediatr 2021;9:626232. [PMID: 33604319 DOI: 10.3389/fped.2021.626232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
429 Ajbar A, Cross E, Matoi S, Hay CA, Baines LM, Saunders B, Farmer AD, Prior JA. Diagnostic Delay in Pediatric Inflammatory Bowel Disease: A Systematic Review. Dig Dis Sci 2022. [PMID: 35288834 DOI: 10.1007/s10620-022-07452-5] [Reference Citation Analysis]
430 Colombel JF. Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention. Inflamm Bowel Dis 2018;24:2173-82. [PMID: 29788127 DOI: 10.1093/ibd/izy150] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 16.0] [Reference Citation Analysis]
431 Carlsen A, Omdal R, Karlsen L, Kvaløy JT, Aabakken L, Steinsbø Ø, Bolstad N, Warren D, Lundin KEA, Grimstad T. Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease. JGH Open 2020;4:410-6. [PMID: 32514446 DOI: 10.1002/jgh3.12266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
432 Watanabe Y, Mizushima T, Okumura R, Fujino S, Ogino T, Miyoshi N, Takahashi H, Uemura M, Matsuda C, Yamamoto H, Takeda K, Doki Y, Eguchi H. Fecal Stream Diversion Changes Intestinal Environment, Modulates Mucosal Barrier, and Attenuates Inflammatory Cells in Crohn's Disease. Dig Dis Sci 2021. [PMID: 34041649 DOI: 10.1007/s10620-021-07060-9] [Reference Citation Analysis]
433 Turri G, Carvello M, Ben David N, Spinelli A. Intriguing Role of the Mesentery in Ileocolic Crohn's Disease. Clin Colon Rectal Surg. [DOI: 10.1055/s-0042-1743590] [Reference Citation Analysis]
434 McKevitt K, Sahebally SM, Patchett S, O'Toole A, Galvin S, Burke JP. Post-operative pain after laparoscopic right hemicolectomy for Crohn's disease: a case control study. Acta Gastroenterol Belg 2021;84:271-4. [PMID: 34217174 DOI: 10.51821/84.2.271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
435 Baghaei A, Emami MH, Adibi P, Tavakkoli H, Daghaghzadeh H, Tamizifar B, Akbarpour MJ, Hojjatpour B. Inflammatory Bowel Disease Registry and Monitoring: Feasibility Study and Application (Isfahan Inflammatory Bowel Disease Surveillance Project). Int J Prev Med 2019;10:190. [PMID: 31807260 DOI: 10.4103/ijpvm.IJPVM_316_17] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
436 Furfaro F, Dal Buono A, Allocca M, D'Amico F, Zilli A, Gabbiadini R, Danese S. Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale? Life (Basel) 2021;11:649. [PMID: 34357022 DOI: 10.3390/life11070649] [Reference Citation Analysis]
437 Fournier A, Mondillon L, Luminet O, Canini F, Mathieu N, Gauchez AS, Dantzer C, Bonaz B, Pellissier S. Interoceptive Abilities in Inflammatory Bowel Diseases and Irritable Bowel Syndrome. Front Psychiatry 2020;11:229. [PMID: 32300314 DOI: 10.3389/fpsyt.2020.00229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
438 Toyonaga T, Steinbach EC, Keith BP, Barrow JB, Schaner MR, Wolber EA, Beasley C, Huling J, Wang Y, Allbritton NL, Chaumont N, Sadiq TS, Koruda MJ, Jain A, Long MD, Barnes EL, Herfarth HH, Isaacs KL, Hansen JJ, Shanahan MT, Rahbar R, Furey TS, Sethupathy P, Sheikh SZ. Decreased Colonic Activin Receptor-Like Kinase 1 Disrupts Epithelial Barrier Integrity in Patients With Crohn's Disease. Cell Mol Gastroenterol Hepatol 2020;10:779-96. [PMID: 32561494 DOI: 10.1016/j.jcmgh.2020.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
439 Bai R, Sun D, Chen M, Shi X, Luo L, Yao Z, Liu Y, Ge X, Gao X, Hu GF, Zhou W, Sheng J, Xu Z. Myeloid cells protect intestinal epithelial barrier integrity through the angiogenin/plexin-B2 axis. EMBO J 2020;39:e103325. [PMID: 32510170 DOI: 10.15252/embj.2019103325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
440 Eckel A, Lee D, Deutsch G, Maxin A, Oda D. Oral manifestations as the first presenting sign of Crohn's disease in a pediatric patient. J Clin Exp Dent 2017;9:e934-8. [PMID: 28828164 DOI: 10.4317/jced.53914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
441 Wang F, Numata K, Yonezawa H, Sato K, Ishii Y, Yaguchi K, Kume N, Hashimoto Y, Nishio M, Nakamori Y, Ikeda A, Madarame A, Hirayama A, Ogashiwa T, Sasaki T, Jin M, Hanzawa A, Shibata N, Hashimorto S, Saigusa Y, Inayama Y, Maeda S, Kimura H, Kunisaki R. Consistency of Trans-Abdominal and Water-Immersion Ultrasound Images of Diseased Intestinal Segments in Crohn's Disease. Diagnostics (Basel) 2020;10:E267. [PMID: 32365572 DOI: 10.3390/diagnostics10050267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
442 Schmitt H, Neufert C, Neurath MF, Atreya R. Resolution of Crohn's disease. Semin Immunopathol 2019;41:737-46. [PMID: 31552470 DOI: 10.1007/s00281-019-00756-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
443 Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier J-F, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel J-F, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020;159:481-491.e483. [PMID: 32425234 DOI: 10.1053/j.gastro.2020.05.032] [Cited by in Crossref: 265] [Cited by in F6Publishing: 269] [Article Influence: 132.5] [Reference Citation Analysis]
444 Bekkers M, Stojkovic B, Kaiko GE. Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease. Int J Mol Sci 2021;22:11243. [PMID: 34681902 DOI: 10.3390/ijms222011243] [Reference Citation Analysis]
445 Jung ES, Lee SP, Kae SH, Kim JH, Kim HS, Jang HJ. Diagnostic Accuracy of Fecal Calprotectin for the Detection of Small Bowel Crohn's Disease through Capsule Endoscopy: An Updated Meta-Analysis and Systematic Review. Gut Liver 2021;15:732-41. [PMID: 33361549 DOI: 10.5009/gnl20249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
446 Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M. The Controversial Role of Human Gut Lachnospiraceae. Microorganisms 2020;8:E573. [PMID: 32326636 DOI: 10.3390/microorganisms8040573] [Cited by in Crossref: 104] [Cited by in F6Publishing: 108] [Article Influence: 52.0] [Reference Citation Analysis]
447 Han X, Ding S, Jiang H, Liu G. Roles of Macrophages in the Development and Treatment of Gut Inflammation. Front Cell Dev Biol 2021;9:625423. [PMID: 33738283 DOI: 10.3389/fcell.2021.625423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
448 Wang X, Li X, Guo X, Liu L, Jin Y, Lu Y, Cao Y, Long J, Wu H, Zhang D, Yang G, Hong J, Yang Y, Ma X. LncRNA-miRNA-mRNA Network Analysis Reveals the Potential Biomarkers in Crohn’s Disease Rats Treated with Herb-Partitioned Moxibustion. JIR 2022;Volume 15:1699-716. [DOI: 10.2147/jir.s351672] [Reference Citation Analysis]
449 Chervy M, Barnich N, Denizot J. Adherent-Invasive E. coli: Update on the Lifestyle of a Troublemaker in Crohn's Disease. Int J Mol Sci 2020;21:E3734. [PMID: 32466328 DOI: 10.3390/ijms21103734] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
450 Liso M, De Santis S, Scarano A, Verna G, Dicarlo M, Galleggiante V, Campiglia P, Mastronardi M, Lippolis A, Vacca M, Sobolewski A, Serino G, Butelli E, De Angelis M, Martin C, Santino A, Chieppa M. A Bronze-Tomato Enriched Diet Affects the Intestinal Microbiome under Homeostatic and Inflammatory Conditions. Nutrients 2018;10:E1862. [PMID: 30513801 DOI: 10.3390/nu10121862] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
451 Hanzel J, Bukkems LH, Gecse KB, D'Haens GR, Mathôt RAA. Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2021;54:1309-19. [PMID: 34559426 DOI: 10.1111/apt.16609] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
452 Lim D, Kim W, Lee C, Bae H, Kim J. Macrophage Depletion Protects against Cigarette Smoke-Induced Inflammatory Response in the Mouse Colon and Lung. Front Physiol 2018;9:47. [PMID: 29483875 DOI: 10.3389/fphys.2018.00047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]